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II. Short Summary 
Cystic fibrosis is a genetic disease, which manifests mainly in the lungs of the affected 
patients. Despite early, aggressive antibiotic treatment the patients sooner or later 
develop chronic bacterial lung infections. 
In vitro models can be useful tools in terms of getting a better understanding of this 
disease. Furthermore, they can be advantageous to evaluate safety and efficacy of 
novel drugs and drug delivery systems against the pathogens, the most prominent one 
being Pseudomonas aeruginosa. 
Aim of this work was to development a model of human bronchial epithelial cells in co-
culture with P. aeruginosa biofilms in order to mimic chronic lung infections as they 
occur in cystic fibrosis. 
The here used human cell line CFBE41o- was characterized thoroughly for morphology, 
barrier properties, permeability and mucus production. Since the cell line does not 
produce mucus, which however plays a major role in the development of chronic CF 
infections, the application of external human mucus was successfully implied. 
Since direct infection with P. aeruginosa and biofilm development on the human cells 
did not lead to a stable model, the application of a preformed biofilm was utilized. 
This model was subsequently used to evaluate safety and efficacy of antibiotic-loaded 
nanoparticles against P. aeruginosa. These particles where nebulized on the co-culture 
and proved to be efficient not only against planktonic but also against the much more 
resistant biofilm grown bacteria. 
 
   
 
- 10 - 
III. Kurzzusammenfassung 
Die angeborene Krankheit Mukoviszidose macht sich vor allem in der Lunge der 
betroffenen Patienten bemerkbar. Trotz frühzeitiger, aggressiver 
Antibiotikabehandlung leiden die Patienten irgendwann an einer chronischen 
Lungenentzündung. 
In vitro Modelle sind äußerst hilfreich um diese Krankheiten besser zu verstehen. Sie 
können außerdem dazu genutzt werden neue Arzneistoffe und Wirkstoffträger auf ihre 
Sicherheit und Wirksamkeit gegen Problemkeime zu untersuchen, allen voran sei hier 
Pseudomonas aeruginosa genannt. 
Ziel dieser Arbeit war es ein solches Modell, bestehend aus humanen 
Bronchialepithelzellen in Co-Kultur mit P. aeruginosa Biofilmen, welches die chronische 
Lungenentzündung bei Mukoviszidose widerspiegelt, zu entwickeln. 
Die verwendeten Zellen wurden eingehend charakterisiert. Da sie keinen Mukus 
produzieren und dieser eine wichtige Rolle bei der Manifestation der chronischen 
Lungenentzündung spielt, wurde externer humaner Mukus für das Modell verwendet. 
Eine direkte Infektion der Zellen mit P. aeruginosa und anschließender 
Biofilmentwicklung, führte zum vorzeitigen Tod der humanen Zellen. Daher wurde ein 
vorgeformter Biofilm auf die Zellen aufgebracht, um ein stabile Co-Kultur zu erhalten. 
Dieses Modell wurde nun genutzt um die Sicherheit und Effektivität antibiotika-
beladener Nanopartikel gegen P. aeruginosa zu testen. Die auf die Co-Kultur 
vernebelten Partikel erwiesen sich sowohl gegen planktonische als auch gegen im 
Biofilm gewachsenen Bakterien als äußerst wirksam. 
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1.1 Cystic fibrosis and how it effects the respiratory tract 
1.1.1 Genetic backround 
More than 80,000 people worldwide are affected by the genetic disease cystic fibrosis 
(CF) [1]. It can be considered as the severest autosomal recessive disorder in Caucasians 
with an incidence of about one in 3500 live births. CF is also found in other ethnic 
groups but to a much lower extent [2, 3]. Despite huge improvements in disease 
management and treatment, life expectancy is still below 50 years [4]. 
CF was first described in 1938 [5] but it took over half a century until the responsible 
gene was identified in 1989 [6]. Mutations in this gene result in malfunction of the 
cystic fibrosis transmembrane conductance regulator (CFTR) protein. The CFTR is a 
cAMP-regulated chloride and bicarbonate ion channel [7, 8]. It can be found in the 
apical plasma membrane of different epithelial cells in the body. In addition, the CFTR 
regulates other ion channels and thus, has a crucial role in fluid homeostasis . Today 
around 2,000 different mutations have been identified since the gene was first 
discovered [7]. However, just a small fraction of these mutations are accountable for 
the clinical symptoms of CF [8]. The known mutations can be categorized in functional 
classes, whereas each class marks mutations that affect the protein synthesis or 
function at different stages [7, 9]. Today a distinction between seven different classes is 
made. Mutations belonging to class I-III result in defective synthesis, defective 
maturation and processing or blocked regulation of the CFTR, respectively  [9, 10]. 
Mutations found in the classes IV, V and VI are responsible for decreased conductance, 
decreased abundance or increased turnover of the CFTR, correspondingly [9]. In light of 
gene therapy a new class VII was added to the system by De Boeck and Amaral [1]. Here 
mutations of class I that per se cannot be rescued with gene therapy (e.g., large 
deletions) are categorized [1]. However, since this subdivision approach of class I would 
require precise knowledge of the molecular pathology it’s discussed controversial [11, 
12]. Nonetheless, the classes I-III and the new class VII are associated with severe 
disease and classic phenotypes of CF [9]. Gene therapy options for patients with such 
mutations are very limited to none. Thus, class I-III and VII should be closely related in 
any kind of system [12, 13]. 
The most common mutation occurring in almost 90% of CF cases is F508del [7]. It 
belongs to category II and results in a misfolding of the protein. The immature mutant 
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is retained in the endoplasmatic reticulum and degraded prior to reaching the apical 
cell surface [1]. This in turn severely reduces the CFTR function and leads to the typical 
CF hallmarks. 
1.1.2 Hallmarks of cystic fibrosis 
Cystic fibrosis is a multi-organ disease. The lacking CFTR activity causes ion, pH, and 
fluid imbalances. The dilatation of exocrine glands and there abnormally viscous 
mucosal secretions lead to obstruction in the pancreatic ducts (exocrine pancreatic 
insufficiency results in fat maldigestion), intestine (e.g., meconium ileus, fatal if left 
untreated) and bile canaliculi (leading to hepatic damage). Male patients are often 
infertile [2, 14, 15]. In addition secondary diseases like diabetes mellitus, distal 
intestinal obstruction syndrome, and CF-related bone disease (e.g., osteoporosis) can 
manifest [2]. 
However, the thick and sticky secretions (i.e., mucus) obstructing the airways are the 
major hallmark of CF. The accumulating mucus offers good growth conditions for 
bacteria and thus, leads to persistent and recurrent lung infections, the major cause for 
morbidity and mortality in patients [16, 17]. 
Usually, in the lungs of healthy individuals inhaled pathogens and particles get 
entrapped in the pulmonary mucus secreted by goblet cells [18, 19]. Another secretory 
cell type contributing to the respiratory lining fluid (mucus) are the club cells (formerly 
known as Clara cells). These non-ciliated cells secrete a number of anti-inflammatory 
and immunomodulatory substances (e.g., the club cell secretory protein). Furthermore, 
they have a high xenobiotic metabolism, and a regenerative role as progenitor cells for 
ciliated cells and themselves [19]. 
These two cell types (i.e., goblet and club cells) are ubiquitous in the epithelial surface 
of the lung. The mucus secreted by them gets subsequently cleared from the lungs by 
cilia-generated forces. This process, also called mucociliary clearance (MCC) is the 
primary defense mechanism protecting our airways. An important component of this 
innate defense mechanism is the airway surface liquid (ASL). It consists of two layers: 
the already mentioned mucus layer on top of the cilia (varying in height) and the 
periciliary liquid layer (PCL), which has roughly the height of the outstretched cilia [20, 
21]. The PCL can be found in the mucus-free area at the epithelial cell surface. It has a 
lower viscosity than the mucus, thus allowing for rapid beating of the enclosed cilia. 
Introduction
 
- 14 - 
Furthermore, the PCL keeps the mucus layer at distance from the underlying epithelial 
cells [20, 21]. 
In addition, the ASL contains antibacterial substances (e.g., lysozyme), cells of the 
immune system (e.g., macrophages), signalling molecules, and cytokines [20]. The CFTR 
facilitates ASL. The chloride ions secreted by the CFTR draw water from the epithelial 
cells and therefore hydrated the PCL and mucus. In CF-lung the hydration of the ASL is 
altered resulting in viscous, “dehydrated” airway mucus. Also the PCL is less hydrated 
and has a depleted volume, which in turn impedes cilia beating, compresses them and 
eventually stops mucus clearance completely [21]. The now resulting immobile mucus 
offers perfect conditions for inflammation and bacterial infection, leading to chronic  
lung disease typical for CF [18]. In addition, several studies imply that the excessive 
pulmonary inflammatory responses seen in CF patients might be related to a defect in 
the adaptive immune responses [22]. The differences of ASL composition in healthy and 
CF lung are shown in Figure 1.1. 
 
 
Figure 1.1: Airway surface liquid composition in healthy and CF lung. In the healthy lung (A) 
the cilia can beat freely in the periciliary liquid layer (PCL), and thus clear inhaled particles and 
pathogens from the lungs (mucociliary clearance, MCC). In the CF lung (B) the mucus layer is 
less hydrated and therefore more viscous. Also, the PCL has a higher viscosity and ciliary 
beating is inhibited. The MCC is coming to a stop. Inhaled pathogens cannot be cleared from 
the lungs and the accumulating mucus offers good growth conditions for them. This leads to 
the chronic colonization of the lungs with bacteria. 
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1.1.3 Lung infections in cystic fibrosis 
The infections occurring in the airways of CF patients are polymicrobial and complex 
[23, 24]. Characteristic pathogens found in the lungs of CF patients are Pseudomonas 
aeruginosa, Burkholderia cepacia complex, Staphylococcus aureus, Stenotrophomonas 
maltophilia, Achromobacter xylosoxidans, Haemophilus influenza and nontuberculous 
mycobacteria. Interestingly, the microbiota changes in the lifetime of a CF patient (see 
Figure 1.2) [24, 25]. Typically, H. influenza and S. aureus are found in the lungs of young 
children. The increasing number of methicillin-resistant Staphylococcus aureus (MRSA) 
infections can be explained by the rising number of hospitalizations throughout the life 
of CF patients since the infection with MRSA is primarily healthcare associated [25]. 
 
 
Figure 1.2: Prevalence of respiratory microorganisms by age.  Prevalence of different 
pathogens changes during the lifetime of a CF patient. While in children S. aureus is most 
prominent, P. aeruginosa is the major microorganism in adult patients. Reprinted with 
permission of [25]. 
 
However, incidence of S. aureus and MRSA decline later in life and infections with the 
facultative anaerobe Gram-negative pathogen P. aeruginosa become more prominent 
in adolescence. More than 70% of adult CF patients are chronically infected with this 
pathogen [26]. The occurrence of multidrug-resistant P. aeruginosa (MDR-PA) infection 
is most prominent in older adolescents and adults with CF. These findings are most 
likely related to the cumulative exposure to antibiotics of those patients. However, the 
clinical significance of this drug resistance is unclear [25]. The main reason current 
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therapies against bacterial infection in CF patients fail, is P. aeruginosa’s ability to build 
antibiotic-resistant biofilms [27, 28]. 
1.1.4 Biofilm development 
P. aeruginosa is one of the most extensively studied biofilm formers [29], however, our 
ability to eradicate infections with this pathogen are still insufficient. This is also due to 
the fact that bacteria living in biofilms can be up to thousand-fold more resistant to 
antibiotics than their planktonic counterparts [30]. The stages of such a biofilm 
development are shown in Figure 1.3. 
Biofilms are dense microbial aggregates. The bacteria are attached to a surface or each 
other and are surrounded by a self-produced matrix of highly hydrated extracellular 
polymeric substances (EPS) [31, 32]. This matrix is primarily composed of 
exopolysaccarides, proteins, extracellular DNA (eDNA), lipids and the main component 
water [32]. The EPS matrix has various functions in a biofilm. It allows the adhesion of 
the biofilm to a surface (i.e., biotic or abiotic) and enables the aggregation of the 
bacteria to each other. It is the structural element determining the mechanical stability 
and architecture of the biofilm. The EPS maintains a hydrated microenvironment 
around the bacteria even allowing survival in water-deficient surroundings. Though the 
sorption of organic and inorganic compounds the EPS also serves as a nutrient source 
for the bacteria residing in it [32]. The eDNA allows genetic information to be 
exchanged between biofilm cells via horizontal gene transfer. The EPS is not a solid 
structure. Proteins (i.e., enzymes) in the EPS can degrade parts of the structural EPS 
and thus allowing cell release from the biofilm. In the light of treating biofilm 
infections, the function of the EPS as a protective barrier seems most important. It not 
only serves as protection from specific and nonspecific host defence mechanisms 
during an infection, the EPS also allows for more tolerance to numerous antimicrobial 
agents (e.g., antibiotics, disinfectants) [32, 33]. This barrier represented by the EPS can 
also lead to low diffusion rates or even failing penetration of antibiotics into the 
biofilm. One example in P. aeruginosa biofilms is the interactions of positively charged 
antibiotics (e.g., Tobramycin) and negatively charged exopolysaccharide (e.g., alginate) 
resulting in hindered penetration of the antibiotic [34, 35]. Furthermore, the enzymatic 
activity of the EPS can cause the inactivation of antibiotic drugs [36, 37]. However, the 
main reason for failure of antibiotic therapies is the changed metabolism of 
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P. aeruginosa in parts of the biofilm. The low metabolic activity in these subpopulations 
of the biofilm is due to low oxygen concentration and nutrient supply in the inner parts 
of the biofilm [34, 38]. These conditions result in slow cell division rates and/or 
anaerobic growth. This in turn, can limit the efficiency of antibiotics like ß-lactams or 
aminoglycosides, which target actively dividing bacteria or aerobically growing 
pathogens, respectively [39]. 
 
 
Figure 1.3: Development of a biofilm. At stage 1 the bacteria attach reversibly to a surface. At 
stage 2 they are already attached irreversibly to the surface and they lose their flagellar 
motility. This step is mainly mediated by the EPS. In the third stage first biofilm maturation 
visible by the development of early biofilm architecture is evident. In the subsequent stage (4) 
the maturation is complete and the biofilm exhibits a complex architecture. In the further 
development (stage 5) single motile cells (dark bacteria in image) can detach from the biofilm 
and can start new microcolonies somewhere else. This biofilm development step is also called 
dispersion stage. Adapted with permission from [40]. 
 
The differentiation of a biofilm is related to bacterial cross-talk, the so-called quorum 
sensing (QS). These signals control the expression of several genes in a cell-density-
related manner [41]. In addition, the production of several virulence factors (e.g., 
extracellular enzymes and cellular lysins like rhamnolipids) is coordinated by the QS 
system. These virulence factors play a major role for the pathogeneses of infections as 
they protect the bacteria from phagocytes [31, 37]. 
The best described QS molecules of Gram-negative bacteria like P. aeruginosa are the 
N-acyl-l-homoserine lactones (AHL). These AHL molecules vary among bacteria, and 
some bacteria exhibit several AHL molecules. However, they all display the same 
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essential structure, an acyl chain of variable length. When the AHL molecules bind to 
their specific receptor (i.e., R receptor) they form an activated complex. This complex in 
turn binds to specific regulator upstream of the promoter region and subsequently 
regulates the target gene transcription in a positive or negative way (e.g., upregulation 
of virulence factor) [42]. 
The major QS systems in P. aeruginosa are the AHL systems encoded by las and rhl [42, 
43]. On top, P. aeruginosa also expresses a quinolone signal pathway [44]. This 
Pseudomonas quinolone signal (PQS) encoded by pqs genes offers an additional QS 
regulatory pathway. These three systems are hierarchically arranged. The las system 
controls the rhl system, while the pqs system functions as a mediator between the two, 
but is also regulated from las system [43, 45]. 
All three systems (i.e., las, rhl and pqs) play an important role in the initiation and 
coordination of biofilm formation. P. aeruginosas ability to build such a self-produced 
matrix can be compromised when the QS system is defective [46, 47], thus, making this 
a promising target for the treatment of the P. aeruginosa biofilm infections [47]. 
Recently, a fourth QS system was discovered in P. aeruginosa, the integrated quorum 
sensing system (IQS) and its corresponding signal [48]. Via this system the integration 
of environmental changes and stress into the bacterial QS signaling is possible (e.g., the 
phosphate depletion that the pathogens often come upon during the establishing of 
infections [48, 49]). Furthermore, it can regulate the pqs system and contributes to 
bacterial virulence in host animal models (e.g., mouse and zebrafish). However, its role 
in P. aeruginosa infections and biofilm formation are not fully understood yet and need 
further investigation [48, 50]. 
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1.2 Treatment of cystic fibrosis 
Thanks to huge treatment improvements median survival of CF patients has increased 
steadily. While patients rarely reached the age of 2 in 1938 [5] and in 1989, when the 
genetic background of the disease was revealed, barely turned 30 years, nowadays the 
median predicted survival age is almost 48 years [4, 25]. This increase in median 
survival age results mainly from early disease diagnosis (i.e., newborn screening 
programs), as well as timely screening for common CF associated comorbidities (e.g., 
diabetes or distal intestinal obstruction syndrome). In addition, also the establishment 
of dedicated CF care centers and evidence-based guidelines, and the implementation of 
therapies in order to improve pulmonary function and nutrition have contributed to 
that success [4, 51]. The routine care should examine CF patients at the least 4 times 
per year and determine the pulmonary function and microbiology as well as the 
nutritional status (e.g., growth and body weight in children or body mass index in 
adults). In addition, specific blood tests (e.g., for inflammatory markers) should be 
performed once a year [52]. 
As mentioned earlier, CF is a disease mostly affecting the lungs. However, since also 
malnutrition due to pancreatic insufficiency and diabetes are very common in CF 
patients, an optimized nutritional status in addition to a therapy maintaining 
pulmonary function are key factors to improve the survival with this disease. 
Furthermore, a good nutritional status is associated with better pulmonary function 
and survival in CF patients [51]. In general, a high caloric and fat enriched diet, 
supplementation of fat-soluble vitamins and the pancreatic enzyme replacement 
therapy are the standard care to improve the nutritional status. CFTR modulators  like 
the CFTR potentiator ivacaftor (Kalydeco®) can further increase that. Treatment with 
this modulator can enhance pancreatic function and bodyweight, helps to control 
diabetes in addition to reducing pulmonary exacerbations and improving respiratory 
function [51, 52]. 
For the pulmonary manifestation the enhancement of the mucociliary clearance (MCC), 
prevention of P. aeruginosa infections, suppression of chronic colonization, and 
treatment of the airway inflammation are the major goals [53]. In order to increase the 
MCC and clear the lung of the thick mucus, inhaled mucolytics (e.g., recombinant 
human DNase, dornase alfa, Pulmozyme®) are administered [53, 54]. Also, the 
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rehydration of the ASL and viscous mucus via inhalation of hypertonic saline, often 
preceded from a bronchodilator, can improve the MCC and lung function [54-56]. In 
addition, physiotherapy is an important component of treatment. It usually consist of 
airway clearance techniques, especially after administering inhaled mucolytic 
substances, and physical exercise [52]. 
As shown in Figure 1.2, bacterial burden changes during the life of a CF patient. 
However, the major pathogen in adult patients is P. aeruginosa, the leading cause of 
morbidity and mortality in CF patients [57, 58]. Once a biofilm is established by these 
bacteria eradication is almost impossible. Therefore, prevention of P. aeruginosa 
infections is mandatory in CF disease management [53]. With an early aggressive 
antibiotic treatment, as conducted now in many cystic fibrosis centers around the 
world, this is trying to be achieved [59, 60]. This treatment usually consists of inhaled 
antibiotics like tobramycin and colistin, oral and intravenous antibiotics like 
ciprofloxacin and combinations of aminoglycosides and beta-lactams, respectively [61, 
62]. Even though patients receive these preventive and aggressive therapies and 
usually are monitored on a frequent basis for bacterial infections, the chronic 
colonization with P. aeruginosa is often inevitable once a biofilm is formed [62]. These 
bacterial biofilms causing the chronic infections show increased tolerance to the innate 
and adaptive immune system, phagocytosis and the administered antibiotics  [53, 63]. 
Nonetheless, high doses and long-term administration of inhaled and intravenous 
antibiotics like tobramycin, aztreonam, and colistin in combination with mucolytics and 
physiotherapy can at least suppress the chronic infection temporarily [64, 65]. 
The exaggerated inflammatory response occurring in acute and chronic infections  are 
an additional challenge in CF therapy. Here, the use of anti-inflammatory agents (i.e., 
macrolides like azithromycin or high doses of ibuprofen) can at least decrease 
respiratory exacerbations and slightly improve pulmonary function [53, 66]. 
Interestingly, common anti-inflammatory drugs used in asthma care like corticosteroids 
lack efficacy in CF [64, 67]. 
All taken together, even though enormous progress has been made in the last decades, 
treatment of CF and the resulting infection with P. aeruginosa is far from optimal. For 
that reason, novel drugs and treatment approaches are mandatory. 
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1.3 Novel treatment approaches 
1.3.1 Gene therapy 
With the discovery of the CFTR gene in 1989 [6], the idea to treat CF right at its genetic 
basis arose. Due to the fact that only a single gene disorder is involved in CF, no 
specifics about the patient’s genotype are necessary for gene therapy, and treatment 
via the pulmonary route being noninvasive and comparatively easy, raised hopes in 
academia, industry, and patients to have gene therapy options before long. But quite 
soon it became clear, that CF gene therapy was far more complex than initially 
anticipated [7]. The gene transfer to the lungs proofs to be rather difficult due to 
effective intra- and extracellular barriers like the nuclear membrane, airway mucus, 
MCC and immune responses [7, 9]. In addition, the selection of suitable gene transfer 
agents (i.e., viral or nonviral) is not trivial. Nevertheless, several approaches are 
currently under investigation and to some extent already in clinical trials [9, 54]. For 
CFTR modulation it can be distinguished between the potentiators, opening the 
defective CFTR channel at the cell membrane, and CFTR correctors, which can increase 
the trafficking of CFTR protein to the cell surface. In addition, read–through agents can 
help to suppress premature termination codons as they occur in class I mutations [68]. 
The actual gene therapy, trying to deliver functional DNA to the nucleus of lung cells in 
order to get a functional CFTR protein transcribed, has also made it to clinical trials. A 
modest increase in lung function could be noted in the verum group twelve months 
after the treatment with liposomes loaded with plasmid DNA encoding the CFTR gene 
(pGM169/GL67A gene–liposome complex) [69]. Furthermore, with Eluforsen (QR-010) 
an aerosolized RNA oligonucleotide intended to repair CFTR-encoded mRNA in patients 
with the F508del mutation is in clinical phase 1b [9, 54]. 
Even though CF therapy via correction of the CFTR gene is still in its infancy, with the 
recently approved CFTR potentiator, ivacaftor (Kalydeco®), at least a modulation of the 
defective CFTR protein at the cell surface is possible. Unfortunately, only around 5% of 
CF patients with mutations belonging to class III and IV benefit from this therapy [68]. 
However, with lumacaftor/ivacaftor (Orkambi®) and tezacaftor/ivacaftor (SymdekoTM) 
two combinations of a CFTR corrector/potentiator were approved. These combinations 
are also helpful to patients with mutations belonging to other classes, most importantly 
the most common CF mutation F508del [54]. But further research is ongoing and 
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necessary, since still only 55% of the people with CF profit from these CFTR modulators 
and clinical benefits are modest [68, 70]. At the moment combinations of 
tezacaftor/ivacaftor and VX-445 or VX659 are in phase three of clinical trials. Similar to 
SymdekoTM these combinations (CFTR correctors) aim to restore the CFTR function [54]. 
Furthermore, several other CFTR modulators are in phase two at the moment (e.g., 
QBW251, a potentiator, just completed phase 2a) [54]. 
1.3.2 Nanocarriers 
Another innovative approach to treat bacterial biofilms in CF is with anti-infectives 
encapsulated in nanocarriers [71]. These nanostructured carriers can be composed of 
biocompatible and biodegradable polymers (e.g., PLGA), solid lipids, or a mixture of 
solid and liquid lipids [72, 73]. Nanocarriers can be administered as inhalation aerosols, 
and thus minimize the systemic exposure and the related side effects. Furthermore, 
with this administration route the local drug concentration in the lungs can be 
increased [59]. Drug loaded nanocarriers could offer a better penetration into the 
biofilm compared to the free drug due to their size and surface properties. In addition, 
the nanoformulations can protect their anti-infective cargo until it reaches the site of 
action and promise a controlled release of the anti-infective agents [36]. 
1.3.3 Aerodynamic properties of inhaled formulations 
In order to achieve a controlled release of the anti-infective cargo, nanoformulations 
must first be deposited in the lungs by means of inhalation. Thereby, particles can be 
deposited via five different mechanisms. While interception and electrostatic 
precipitation are related to particle shape and electrostatic charges, respectively, the 
other three mechanisms (i.e., inertial impaction, sedimentation and diffusion) are 
related to particle size [74]. However, not only size and shape, but also density 
determines the aerodynamic behaviour of inhaled particles. Thus, the aerodynamic 
diameter combing all three parameters is often referred to. It is defined as the 
diameter of a spherical particle with a density of 1 g/cm³ having the same aerodynamic 
behaviour as the characterized particle [75]. 
Bigger particles (> 1-10 µm) deposit for the most part through impaction and 
sedimentation, while the smaller particles (< 0,1 µm) get deposited mainly via diffusion 
in the deep lung. Of note, particles with a size between 100 nm and 1 µm show the 
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lowest deposition. In view of the fact that particles of that size (0.1 µm-1 µm) are too 
small for impaction and only show a slow diffusion, they are usually exhaled before 
they can deposit [74]. However, most nanocarriers are in that critical size range and for 
that reason not suitable for inhalation as a dry powder. Yet, by formulating a 
nanosuspension of the nanocarriers and applying them with a nebulizer, droplets of the 
right size can be achieved (i.e., ∼1 µm) [76]. However, nebulization devices are not well 
accepted from patients due to long administration times, portability of the device, 
complex cleaning procedures, rather higher costs compared to dry powder devices and 
need for maintenance. Furthermore, nebulization often has a low efficiency and suffers 
from poor reproducibility [59, 77]. By means of reformulating the nanocarriers into 
microparticles (e.g., through spray drying, nanoparticle flocculation), a deposition of 
the particles can be achieved. Since the reformulated nanoparticles attain an 
aerodynamic particle size of 1 – 5 µm, which enables them to reach the lung periphery 
[76]. 
These microparticles can now be applied via a dry powder inhaler and as a result the 
drawbacks of nebulization can be circumvented. Such powders for inhalation are 
typically characterized with the mass median aerodynamic diameter (MMAD) and the 
corresponding geometric standard deviation (GSD). The MMAD is the cut off size at 
which 50% off particles are bigger and 50% are smaller than this median value [74]. 
Furthermore, also the fine particle fraction (FPF) is an important parameter when 
characterizing pharmaceutical formulations for inhalation. The FPF is defined as the 
mass fraction of an inhaled dose with an aerodynamic diameter smaller than 5  µm, and 
thus the amount of powder expected to reach the lung [78]. Typically, these 
parameters (i.e., MMAD, GSD and FPF) are determined with cascade impactors like the 
Next Generation Impactor or the Andersen Cascade Impactor [74]. 
1.3.4 Quorum sensing inhibitors 
Targeting the QS system with quorum sensing inhibitors (QSI) has been proposed 
recently as new anti-virulence strategy. By using such QSIs a reduced production of 
virulence factors, and thus a possible prevention of biofilm formation or other virulence 
mechanisms associated with P. aeruginosa infections can be accomplished [79, 80]. 
However, also several useful bacterial species living in the human body use such QS 
systems. Targeting the QS could therefore lead to unknown side effect. On the other 
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hand, the pqs system is only employed by P. aeruginosa and some Burkholderia species 
making inhibitors for this QS system a promising approach [79, 81]. In order to 
successfully deliver such QSIs to the lungs they can be encapsulated in nanocarriers 
[73]. 
1.3.5 Bacteriophage therapy 
Bacteriophages also showed promising results as potential treatment option against 
antibiotic–resistant bacteria like P. aeruginosa [82]. Phages are viruses targeting and 
infecting only specific bacteria. For that reason, phage therapy can minimize the side 
effects on the natural flora of the patient [83]. Bacteriophages can replicate themselves 
at the infection site, infect the pathogenic bacterium and lyse it. In addition, phages are 
able to evolve, when bacteria develop resistance, and thus are able to regain 
effectiveness [82-84]. Even though antibacterial effects and their specificity are well 
known, their safety to mammalian organisms has not been fully investigated yet [82]. 
Since in vivo studies are time consuming, as well as limited due to ethics and costs, the 
use of suitable animal in vivo models and much more important in vitro models to 
evaluate the safety of these novel nanocarrier and phage therapies are necessary. 
1.4 in vivo models of CF 
Animal models have been widely used to study cystic fibrosis and disease pathogenesis. 
Several animal models have been described such as pig, ferret, rabbit, rat, and mouse 
[85]. However, not all are equally suited to study all aspects of CF. Only the pig and the 
ferret show all organ specific disease markers present in human CF patients (e.g., lung 
infection, impaired growth, intestinal disease, pancreatic and hepatic insufficiency, 
gallbladder failure) [85]. Even though CFTR-knockout mice were engineered 3 years 
after the gene was discovered in 1989 [86, 87], these widely used animal models lack 
the spontaneous lung infection so typical for CF [85]. Thus, alternative mouse models 
exhibiting inflammation and mucus obstruction were developed. They showed 
symptoms of CF lung disease like reduced MCC, mucus accumulation, immune 
responses, a decreased lifespan and the increased susceptibility to bacterial infections 
[85, 88, 89]. Furthermore, mouse and rat models that can mimic the infected lung were 
developed by infecting CFTR knock out animals either intravenously or intratracheally 
with CF relevant pathogens like P. aeruginosa [90]. However, infection of the murine 
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lung can on the one hand easily result in acute sepsis and death of the animal when the 
administered bioburden is too high. On the other hand also a fast clearance of the 
pathogen is possible, since rodents are resistant to P. aeruginosa lung infections by 
nature [91-93]. In both cases, a chronic infection cannot be mimicked for more than a 
few weeks. Yet, by immobilizing the bacteria for example with agar, agarose, seaweed 
or alginate produced by the pathogen itself, also chronic infections can be simulated 
[91, 93, 94]. 
These rodent models helped to study the efficacy and pharmacokinetics of several 
antimicrobials (e.g., azithromycin) [95]. In addition, they were helpful to gain more 
insight in the pathogenesis of biofilm development [90]. 
However, the need for animal models that fully exhibit the human CF phenotype was 
still unsatisfied. Therefore, CF ferret and pig models were developed in 2008 not least 
by implementing the knowledge gained from creating the knockout mice in 1992 [90]. 
These two species show a much closer resemblance to the human lung cell biology than 
mouse, rat, or rabbit, since they contain submucosal glands (SMG) important for mucus 
production. These SMG are not present in rabbits and are limited to the trachea region 
in mouse and rat. The similarity of the ferret and pig models to the human lung 
phenotype enables a fast translation of novel therapies like gene therapy to the human 
situation. However, these two animal models are more resource intensive than for 
example rodent models, and consequently not as widely used [85, 96]. 
Nonetheless, alternative testing methods for novel therapies should be implemented in 
research in order to replace, reduce, and refine animal experiments according to the 3R 
principle of Russell and Burch [97]. 
1.5 in vitro models of CF 
In the last three decades extensive efforts have been made to develop in vitro models 
in order to better understand the molecular and cellular pathophysiology of CF and the 
accompanying infection processes [98]. Since the major problem in CF are the recurring 
and chronic lung infections caused from the biofilm formation of the pathogens, in vitro 
models of different complexity were established to better understand biofilm 
development and to overcome the lack of adequate treatment option. Some of these 
models could already be used to develop and investigate new treatment options for 
cystic fibrosis. In addition, such in vitro models help to reduce animal experiments in 
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preclinical trials and are therefore suitable tools to effectively implement the 3R 
principle. 
A good overview of exicisting in vitro and in vivo biofilm models is given in the review 
by Lebeaux et al. [90] The described models are useful tools to understand the 
development of such complex bacterial communities of one or even more pathogens 
(e.g., P. aeruginosa and S. aureus). Furthermore, they can be used to get a first hint of 
the efficacy of a new drug. 
1.5.1 Biofilm models 
Typically, biofilms grown in vitro are produced in flow cells, spinning-disk reactors, drip 
flow reactors or tube biofilm reactors. Even though these models allow for the growth 
of high density biofilms in continuous and controlled culture conditions, they are 
limited by the small amount of biofilm produced at the same time in order to use them 
as new compound screening tools [99]. Two models offering this high throughput 
option have been developed. One option is to grow the biofilms directly in 96-well 
microtiter plates [100, 101], or the other to cultivate them on peg lids as in the Calgary 
biofilm device [102]. These biofilm models can be utilized with different pathogens 
(e.g., P. aeruginosa) and were already described in 1998. They allow a high throughput 
of test compounds by producing 96 equivalent biofilms and therefore offer the 
opportunity to choose antibiotics effective against biofilm growing bacteria on a 
rational basis [102]. 
However, abiotic grown biofilms (i.e., on glass or plastic like microtiter plates) differ 
significantly from biofilms grown on living tissue. Such biotic grown biofilms can be over 
one hundred times more resistant to antibacterial treatments than biofilm grown on an 
abiotic surface [103]. In addition, abiotic biofilm models do not allow to observe any 
(patho)physiological changes that might occur in the epithelium during the infection 
and some antibiotic therapy, such as cellular viability and epithelial barrier function. 
Thus, in vitro models that offer both, a living lung epithelium and a developing biofilm 
offer huge advantages for the susceptibility testing of novel antibiotic compounds. 
1.5.2 Human lung anatomy 
The human lung epithelium is generally divided into two anatomical regions: the central 
lung (conducting airways) and the deep, peripheral lung (alveolar region) [104]. 
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The thin alveolar epithelium has a squamous nature and is to the most part composed 
of the alveolar type I cells (96%). The cuboidal alveolar type II cells, although greater in 
number, only make up 3% of the alveolar surface area. The extremely thin morphology 
and extensive surface area (140 m²) of the peripheral lung epithelium allows for a rapid 
gas exchange. The apical membranes of the two cell types are connected by tight 
junctions (TJs, also see chapter 3.3.1) resulting in a tight barrier, the air-blood barrier 
[104, 105]. 
Yet, for the treatment of CF, the central lung is the target region of the inhaled 
antibiotics. The pseudostratified airway epithelium has a much smaller surface area 
(1-2 m²). Besides transporting air to the deep lung, the most important function of the 
tight airway epithelium is the mucociliary clearance. The airways are composed of 
ciliated cells, mucous goblet cells, basal cells, serous cells, brush cells, club cells (former 
Clara cells) and neuroendrocrine cells [104, 105]. The cellular composition varies at 
different levels of the airways (starting with nasal epithelium, followed by trachea, 
large and small bronchi and the terminal bronchioles). However, most of the epithelium 
is covered by ciliated cells (most abundant cell type), mucus-producing goblet cells and 
club cells [104]. A mixed primary culture of these human airway epithelial cell types 
would closely resemble the central lung epithelium in vitro [104]. 
1.5.3 Human airway cell culture models 
However, even though human primary cells (e.g., from CF patients) are irreplaceable to 
understand the underlying mechanisms of CF, they have several drawbacks. Due to the 
limited availability of tissue, their elaborate handling, risk of contamination, and 
additionally the terminal differentiation and the limited lifespan of primary cells make 
the use of cell lines a much more convenient alternative as basis for in vitro models 
(e.g., co-culture models of human epithelial cells and typical CF pathogens) [106]. 
Transformed airway epithelial cells can overcome these shortcomings and, in 
comparison to carcinoma cell lines, the original cell type of the transformed cells is 
known. Starting out with engineering cells that exhibit the typical CF mutations, several 
cell lines were generated already in 1995 [106] and over 40 cell lines were available for 
CF research just 10 years later [107]. Even though cell lines can be a result of a 
carcinomas like the widely used bronchial epithelial cell line Calu-3, typically, the 
immortalization of airway epithelial cells is achieved through transformation for 
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example with a simian virus 40 (SV40) based system. One of these cell lines resulting 
from such a transformation is the CFBE41o- cell line [107]. These cells have a human 
bronchial epithelial origin and are homozygous for the most common mutation in CF, 
the ∆F508 mutation. The CFBE41o- cells were systematically characterized and found to 
be useful for example CF gene transfer studies or as screening tool for alternative 
treatments [108]. For this reason, they have been used in several studies with CF 
background (NCBI PubMed database listed 131 studies with these cells in 2018) [109]. 
While subcultures of primary cells and some of the transformed cell lines may lose 
certain differentiated features (e.g., ion transport, secretion, formation of tight 
junctions), a measure to induce differentiation in both primary cells and cell lines, is to 
grow the cells at an air-liquid interface (ALI) [106]. By culturing the cells on permeable 
inserts, and thus providing them with medium from the basolateral side and exposing 
them to air on the apical side, can model the in vivo situation as found in the lung much 
better then submersed cultures (see Figure 1.4 for comparison of culture condition). 
Epithelial cells grown in that way (i.e., ALI) form polarized cell layers. Furthermore, it 
allows to measure their epithelial barrier properties (see also chapter 3.3.1) and apply 
pulmonary drugs in form of aerosols for example with the Pharmaceutical Aerosol 
Deposition Device On Cell Cultures (PADDOCC) system [106, 110]. 
 
 
Figure 1.4: Schematic of culture conditions in a Transwell® system. For liquid-covered 
conditions (LCC) cells are fed with medium from apical and basolateral side. For air -liquid 
interface (ALI) conditions cells receive medium only through the permeable membrane from 
the basolateral compartment. They are exposed to air on the apical side.  
Introduction
 
- 29 - 
Alongside primary cells or other cell lines (e.g., Calu-3, A459) the CFBE41o- cells have 
also been used for co-culture models of human epithelial cells and P. aeruginosa 
biofilms. Such in-vitro models have been described previously by several groups [82, 
103, 111-113]. Partially, these models were cultivated at air-liquid interface conditions, 
but in some cases not during the whole experiment [27, 111]. In addition, the rapid 
bacterial overgrowth of the cultures after the infection with P. aeruginosa resulted in a 
model not viable for more than 8 h [111, 112]. 
Also, organoids as in vitro systems to study the CFTR function might be mentioned here. 
These advanced three-dimensional (3-D) structures are useful tools for disease 
modelling and to screen drugs for their CFTR corrective function (e.g., with the help of 
CRISPR-Cas9) and model regeneration after CFTR repair [85, 114]. In this context the 
widely used lung adenocarcinoma cell line A549 was exploited. These cells seem rather 
unsuitable for an in vitro co-culture model of CF since they lack barrier properties due 
to insufficient expression of tight junction proteins and moreover do not produce 
mucus when grown as monolayers. However, when grown as 3-D aggregate model in a 
rotating-wall vessel, the cells showed increased expression of tight junction proteins 
(e.g., occcludin, ZO-1, E-Cadherin) and polarity. Furthermore, the cells produced 
mucopolysaccharides and antibodies against mucus proteins MUC1 and MUC5A bound 
with higher affinity, when cells were grown as 3-D aggregates in contrast to cells grown 
as monolayers [115]. These findings emphasize the importance of not only choosing a 
suitable cell line but also the right culture conditions for an in vitro model. 
Nonetheless, the properties of the above described models make them unsuitable for 
testing aerosolized medicines. However, inhalable formulations are of the utmost 
importance when treating infections occurring due to CF pathophysiology. In vitro 
models valid to test such formulations for their safety and efficacy are therefore still 
needed. 
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Even though in vitro models of different complexity mimicking cystic fibrosis can be 
found in the literature, a model cultivated at an air-liquid interface, which exhibits the 
typical infection with P. aeruginosa biofilms in cystic fibrosis, does not exist yet. A 
model reflecting this complex situation and at the same time allowing to test new 
aerosolized pharmaceutical formulations would therefore be of great value.  
This thesis was part of the project “cystic Fibrose Delivery” (FiDel). FiDel’s aim was to 
develop and proof the concept of a nano-scaled drug delivery system in order to treat 
chronic P. aeruginosa biofilm infections in cystic fibrosis. Thus, part of this project was 
the establishment of in vitro models of the air-blood barrier of different complexity. 
These models should then be used to evaluate drug delivery systems, also generated in 
this project, for their safety and efficacy. 
As discussed previously, the reproducibility of such a model would benefit from using 
cell lines. Therefore, two cell lines, one as model for the healthy bronchial epithelium, 
and a second one as model cell line for the diseased epithelium were scrutinized. 
Especially their ability to form a tight barrier at liquid-covered conditions, but more 
importantly, when grown at an air-liquid interface were inspected. Mucus is a 
significant non-cellular barrier and could, especially in the case of cystic fibrosis, hinder 
the effective treatment with drug delivery systems due to increased amounts of thick 
and sticky mucus. In consequence, the mucus production of both cell lines was 
examined. 
Since the highly viscous mucus is one of the major hallmarks in cystic fibrosis, a mucus 
layer is an important part of an in vitro cystic fibrosis model. Thus, alternative mucus 
sources were probed in the second part of this work. 
In the third part of this thesis the model pathogen P. aeruginosa PAO1 was 
characterized for its ability to build biofilms on abiotic and biotic surfaces like epithelial 
lung cells and the optimal biofilm growth conditions were evaluated. 
With the knowledge gained from these first three chapters, the main aim to establish 
an in vitro model of P. aeruginosa biofilms on the apical surface of tight human 
bronchial epithelial cell monolayers, grown at an air-liquid interface, was pursued. Two 
different approaches to such an in vitro tool were assessed. 
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In a fifth section of this work the resulting model was used to test the safety and 
efficacy of aerosolized antibiotic nanocarriers produced in another part of the FiDel 
project. Readouts like the reduction of bacterial burden, as well as maintenance or 
restoration of epithelial cell viability and barrier function were used to evaluate the 
efficacy of the drug delivery systems and the applicability of the in vitro co-culture 
model for such a purpose. 
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3 Characterization and comparison of two human bronchial 
epithelial cell lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The author of the thesis made the following contribution to this chapter:  
 
Planned and performed all cell culture experiments, measured TEER and permeability, 
prepared cells for confocal analysis, histology and scanning electron microscopy and 
took the images, analyzed and interpreted all obtain experimental data and wrote the 
chapter. 
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3.1 Introduction 
Local delivery of antibiotics to the lungs seems the best option to treat chronic 
infections occurring sooner or later in CF patients. To evaluate novel drugs and drug 
delivery systems for their safety and efficacy, a rising need for suitable in vitro models 
has evolved in recent years. In addition, implementation of the 3R principle 
(replacement, reduction, and refinement) in labs all over the world makes such models 
that reduce the use of animals even more valuable. Even though such models are more 
robust, offer simplicity, high throughput and better predictions, they need to be 
thoroughly characterized and later on standardized and validated to use them as tool 
for drug screening in pharmaceutical industry. 
Although primary cells are still considered as gold standard for cell growth in vitro, their 
use is restricted due to unreliable supply, time consuming isolation methods, high 
variability between donors as well as their limited live span [116]. This makes the use of 
continuous cell lines even more convenient [117, 118]. The human-derived cell lines 
A549 (alveolar region), Calu-3 and 16HBE14o- (bronchial region) have already been 
studied extensively. The latter two offer a bronchial epithelial cell-like phenotype and 
the ability to develop barrier properties [104]. Since the aim of this work was a co-
culture model of epithelial cells and bacteria mimicking chronic infections in CF, the use 
of the CFBE41o- cell line (human bronchial origin, homozygous for ∆F508 mutation) was 
also a promising option. To simulate a healthy and CF affected host, Calu-3 and 
CFBE41o- cells, respectively, were therefore considered for this in vitro model. The cells 
should present appropriate barrier properties so as to withstand the infection with 
bacteria and be used for drug delivery experiments later on. Also, the production of 
mucus by the cells seems mandatory, since the accumulation of thick and sticky mucus 
plays a key role in CF disease and the development of chronic infections with 
P. aeruginosa. 
Although Calu-3 cells are already well described in the literature and also several 
studies regarding the CFBE41o- cells have been published, both cell lines were 
cultivated again under liquid-covered conditions as well as at the air-liquid interface to 
be compared. They were further characterized regarding their ability to develop barrier 
properties by way of measuring transepithelial electrical resistance (TEER), staining of 
the tight junction (TJ) protein occludin and permeability studies using the paracellular 
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transported marker sodium fluorescein (NaFluo). Also, the secretion of mucus under 
the different culture conditions was assessed for both cell lines with acridine orange 
(AO) and peridoc acid-Schiff/Alcian blue staining (PAS/Alcian blue). In addition, 
scanning electron microscopy (SEM) images were taken to get more insight into cell 
morphology and mucus production. 
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3.2 Material and Methods 
3.2.1 Cell culture 
CFBE41o- cells were received as a kind gift from Dr. Dieter C. Gruenert (University of 
California, San Francisco, CA, USA) and passages 4.74 to 4.94 were used for 
experiments. Cells were cultivated in Minimal Essential Medium (MEM, Gibco™ Thermo 
Fisher Scientific Inc., Waltham, MA, USA) supplemented with 10% fetal calf serum (FCS, 
Lonza, Basel, Switzerland), 1% non-essential amino acids (NEAA, Gibco™) and 600 mg/l 
glucose (Sigma-Aldrich, Munich, Germany) at 5% CO2 atmosphere, 95% relative 
humidity, and 37°C in T75 cell culture flasks (Corning, Wiesbaden, Germany). Calu-3 
cells (clone HTB-55) were obtained from American Type Culture Collection (ATCC; 
Rockville, MD, USA) and used from passage 31-51 and cultivated in MEM supplemented 
with 10% FCS, 1% NEAA and 1% sodium pyruvate (Gibco™, Thermo Fisher Scientific Inc., 
Waltham, MA, USA) under the same conditions as the CFBE41o- cells. Cells were fed 
every 2-3 days with fresh medium and passaged weekly to a new T75 flask with a 
density of 2x105 cells (CFBE41o-) or 2x106 cells (Calu-3). For further experiments both 
cell lines were seeded with a density of 0.5x105 (CFBE41o-) or 1x105 (Calu-3) into 12 
well Transwell® (Corning, Wiesbaden, Germany) plates with a pore size of 0.4 µm and 
1.12 cm² growth area per well. For liquid-covered conditions (LCC) medium was set to 
500 µl apical and 1500 µl basolateral. To achieve air-liquid interface (ALI) conditions, 
typically 2-3 days after seeding of the cells, medium was removed from both 
compartments and only 500 µl medium was added to the basolateral compartment. 
To evaluate the influence of seeding density and culture time on mucus production , the 
CFBE41o- cells were additionally also seeded with a density of 0.25 x105/per insert into 
a 12 well Transwell® plate, lifted to ALI 2-3 days after seeding and cultivated in that way 
up to 10 days. Medium was changed 3 times per week in all cases.  
3.2.2 Transepithelial electrical resistance (TEER) 
To determine the confluence of cell monolayers and tightness of their intercellular 
junctions, the transepithelial electrical resistance (TEER) can be measured [119]. Cells 
on Transwell® filters were taken out of the incubator and placed on a heating plate to 
avoid TEER fluctuations due to temperature change. Medium from cells cultivated at 
ALI conditions was replenished to 1500 µl basolateral and 500 µl apical and cells were 
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left to equilibrate for 30 min. Electrical resistance of cell layers was measured with 
chopstick electrodes connected to an epithelial voltohmmeter (EVOM; World Precision 
Instruments, Sarasota, FL, USA). TEER was calculated by subtracting the background 
value of an empty Transwell® containing only medium (110 Ω) and multiplying the 
result with the growth area of the well (1.12 cm²). Cells showing TEER values 
>300 Ω∙cm² were considered to have barrier properties.  After TEER measurement ALI 
conditions were restored. 
3.2.3 Transport studies 
Transport studies are a useful tool to measure the permeability of cell monolayers for 
specific marker molecules and to evaluate their suitability for drug transport studies. 
The hydrophilic marker sodium fluorescein (NaFluo) is primarily transported via the 
paracellular route and can therefore be used as an indicator of tightness of the TJs that 
control this pathway. The calculated parameter in such studies is the apparent 
permeability coefficient (Papp), which describes the percentage of a compound 
transported over a certain area over time [104]. It can give a hint to the potential 
bioavailability of the compound in vivo [119]. In order to determine the Papp (cm/s) as a 
function of the used culture conditions, Calu-3 and CFBE41o- cells were seeded on 
Transwell® plates as described in chapter 3.2.1. Two to three days after seeding cells 
were divided into two groups. They were either further cultivated under LCC or lifted to 
ALI. To monitor cell growth and determine the day when the cells show barrier 
properties, TEER values were measured every 2-3 days as described above (see chapter 
3.2.2). When cells showed considerable barrier properties (usually on day 10 or 5 after 
seeding for Calu-3 and CFBE41o- cells, respectively) transport studies were performed 
according to a previous protocol [120] with small modifications. Briefly, before starting 
the transport experiment TEER values were measured as specified under 3.2.2. 
Afterwards, cells were washed twice with 37°C warm Krebs-Ringer Buffer (KRB; 
NaCl 142.03 mM, KCl 2.95 mM, K2HPO4*3H2O 1.49 mM, HEPES 10.07 mM, 
D-glucose 4.00 mM, MgCl2*6H2O 1.18 mM, CaCl2*2H2O 4.22 mM; pH 7.4) and then 
further incubated with 500 µl apical and 1500 µl basolateral pre-warmed buffer for 
another 60 min. TEER values were measured again. Buffer was then removed and 
replaced with 520 µl of NaFluo solution (10 µg/ml in KRB) to the apical compartment 
(donor), as well as 1700 µl of fresh KRB to the basolateral compartment (acceptor) of 
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the Transwell®. Directly after adding the marker solution, samples were taken from 
both compartments (20 µl apical and 200 µl basolateral) and transferred to a 96-well 
plate. Further samples of 200 µl were taken from the basolateral compartment every 
30 min for 3 h and sample volume was replaced each time with 200 µl fresh pre-
warmed KRB. During the experiment the Transwell® plates were kept in the incubator 
at 37°C on a horizontal shaker with constant rotation speed (150 rpm). After the last 
sampling from the acceptor another sample from the apical compartment (20 µl) was 
taken to determine the final concentration of the donor. TEER was measured again at 
the end of the experiment to assure that the integrity of the monolayer was not 
compromised throughout the course of the experiment. All taken samples were 
measured with a plate reader (TECAN, infinite M200 pro, Männedorf, Switzerland). 
Excitation and emission wavelength were set to 480 nm and 530 nm, respectively. The 
transport properties depending on the setup (LCC ft. ALI) are expressed with different 
apparent permeability coefficients (Papp). This parameter was calculated according to 
the equation: 
    Papp = (∆Q/∆t)*(1/A*C0) 
where, Q, t, A and C0 are the cumulative amount of drug permeated across the cell 
monolayer, time of the experiment, surface area of the Transwell® and the initial donor 
concentration, respectively. 
3.2.4 Confocal laser scanning microscopy (CLSM) 
To visualize differences in TJ pattern due to culture conditions cells were seeded on 
Transwell® filters as described in 3.2.1 and cultivated under LCC or at ALI conditions. 
When cells expressed barrier properties, measured through TEER determination (3.2.2) 
the medium was removed and cells were fixed with formaldehyde (500 µl apical) for 
10 min at room temperature (RT). Fixation was removed and cells washed 3 times with 
Phosphate buffered saline (PBS, 500 µl). To avoid unspecific binding and permeabilize 
the samples were blocked for 10 min with a PBS solution containing 1% bovine serum 
albumin (BSA) and Tween. Solution was removed and the primary antibodies against 
the TJ protein occludin (mouse anti-occludin, Catalog No 33-1500, Invitrogen, Carlsbad, 
USA) and against the cytokeratin (rabbit anti-cytokeratin, catalog No Z0622, DAKO, 
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Santa Clara, USA) were diluted 1:500 in PBS and incubated with the cells at 4°C over 
night. Primary antibodies were removed and cells washed 3 times with PBS (500 µl) and 
blocked again with 1% BSA solution in PBS for 10 min at 37°C and subsequently washed 
once with PBS. Secondary antibodies for occludin (goat anti-mouse Alexa Fluor 633, 
Catalog No A21050, molecular Probes, Eugene, USA) and cytokeratin (swine anti-rabbit-
FITC, Catalog No F 0054, DAKO) were diluted 1:500 in PBS and cells were incubated with 
secondary antibody for 1 h at 37°C. Cells were then washed once and nuclei stained 
with propidium iodide (PI, 1:2000 in PBS) for 3 min at RT. Samples were washed 2 times 
and filters cut from Transwell® inserts, placed on an objective slide and enclosed with a 
cover slide. Images were taken with a Carl Zeiss Laser scanning system LSM 510 (Zeiss, 
Jena, Germany). Excitation wavelengths were set to 488 nm and 633 nm for cytokeratin 
(green) and occluding (red) signal, respectively. Using the 100x oil immersion objective 
(EC Plan-Neofluar 100x/1.3 Oil M27) images were taken with a 1024×1024 resolution 
and processed with Fiji software (ImageJ 1.48r, Rasband W., National Institute of 
Health, USA [121, 122]). 
3.2.5 Scanning electron microscopy (SEM) 
For scanning electron microscopy (SEM) preparation medium was removed from the 
cells and cells washed once with PBS. Afterwards they were fixed with a 
formalin/glutaraldehyde solution for 45 min at RT. Samples were then washed with PBS 
and de-hydrated with a graded series of ethanol (30-100%). After removing ethanol 
100%, hexamethyldisilazane (HMDS, Sigma Aldrich) was added for another 10 min to 
achieve a complete de-hydration. HMDS was then removed and Transwells® placed 
under fume hood to allow organic solvent residues to evaporate. Filters were then cut 
from inserts and mounted on aluminium stubs, which were equipped with a carbon 
disc. Samples were sputtered with gold (Quorum Q150R ES, Quorum Technologies Ltd, 
Laughton, UK) and images taken with an EVO HD 15 microscope (acceleration voltage 
5kV; Software SmartSEM, Zeiss, Jena, Germany) under vacuum conditions. 
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3.2.6 Mucus detection with periodic acid-Schiff (PAS) and Alcian blue 
In order to visualize the amount of mucus produced by the cell lines depending on the 
used culture conditions (e.g., LCC or ALI) a PAS/Alcian blue staining for neutral and sour 
mucins was conducted. Medium was removed and cells washed once with PBS. Alcian 
blue solution was then pipetted on the cells for 5 min, cells washed thoroughly with 
water before periodic acid was put on the cells for 10 min. After that step samples were 
washed again with water and subsequently, cells were treated with Schiff's reagent for 
another 15 min. Hereafter, cells were washed again and immediately imaged with a 
light microscope (Vert.A1, Zeiss, Jena, Germany) equipped with a camera (AxioCam 
ERc5s). The objectives wit magnification of 10x and 20x were used. Due to the staining 
sour mucosubstances will appear in bright light-blue and neutral polysaccharides and 
mucopolysaccharides in purple. 
3.2.7 Mucus detection with acridine orange (AO) 
Another staining useful to detect mucus in particular mucoglycoproteins is with  the dye 
acridine orange (AO) [123]. AO is a dye widely used to stain nucleic acids. A green 
fluorescence can be observed when it intercalates with DNA, where as an interaction 
with RNA results in a red fluorescence [124]. This spectral shift can also be observed 
when AO interacts with other sour cell components, e.g., mucins. Mucus containing 
cells will therefore appear red. Staining was performed as described in Teubl et al. 
[125]. Briefly, medium from cells was removed; samples washed once with 100 µl HBSS, 
and stained with a solution of HBSS containing 80 µg/ml AO (Sigma Aldrich) for 10 min 
at 37°C. Staining solution was removed, cells washed twice with 100 µl HBSS, and cut 
from their Transwell® supports. Membranes were placed on objective slides, 
submerged with FluorSave™ (Merck Millipore, Darmstadt, Germany), and covered with 
a cover slide. Samples were imaged with a Carl Zeiss Laser scanning system LSM 510 
(Zeiss, Jena, Germany) right away. Excitation wavelengths were set to 543 nm for red 
signal (mucus) and 477 nm for green signal (cytoplasm). Images with a 1024×1024 
resolution were taken with the 25x water immersion objective (LCl Plan-Neofluar 
25x/0.8 Imm Korr DIC M27) and further analyzed with the Fiji software. 
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3.2.8 Statistical analysis 
Data are presented as mean ± standard error of the mean (SEM) from 2-3 independent 
experiments. Statistical analysis was performed with the GraphPad Prism 5 software. 
The change in Papp depending on the applied culture condition was compared with a 
t-test; p<0.05 was considered significant.  
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3.3 Results and Discussion 
3.3.1 Calu-3 and CFBE41o- cells exhibit tight barriers when cultivated under liquid-
covered conditions (LCC), but only Calu-3 show barrier properties when grown at 
the air-liquid interface (ALI) 
Epithelial barriers are crucial for human survival, because they separate us from our 
external surroundings [126, 127] and represent the first cellular barrier that inhaled 
compounds are confronted with [104]. Tight junctions (TJs) together with adherens 
junctions, gap junctions and desmosomes form this barrier [126]. TJs were first 
discovered in 1963 by Farquhar and Palade with electron microscopy [128]. These 
structures bring neighbouring cell membranes in close contact and result in the 
formation of a permeability barrier for inhaled toxins or pathogens [129, 130], but also 
control the flux of water, ions and other macromolecules between the cells . In addition, 
they maintain epithelial cell polarity [126]. The transmembrane domain of the TJ 
complex contains a minimum of three different proteins: claudin, occluding and 
junctional adhesion molecules (JAMs) [127], but also the more recently identified 
proteins tricellulin and the coxsackie and adenovirus receptor as well as many other 
proteins are associated with the TJ complex [131, 132]. 
The cytoplasmic plaque (i.e., scaffolding, cytoskeletal and adaptor proteins) connects 
the transmembrane proteins to the cytoplasm and function as regulator of adhesion 
and paracellular permeability. Additionally, it is responsible for signal transmission from 
the junction to the inner cell, and thus regulates cellular processes such as gene 
expression and migration [133]. Such peripheral proteins are for example zonula 
occludens ZO-1, -2, -3 and cingulin [134, 135]. 
Today hundreds of proteins are known for their association with the TJs [132, 136]. TJs 
not only regulate the paracellular pathway for molecules of all kind and separate 
different body compartments from one another [137], but they also take an active part 
in gene transcription, regulation of cell proliferation and cellular differentiation [138]. 
In order to analyze the barrier properties of epithelial cells three methods can be 
applied: visualization of TJs with thin section electron microscopy, measurement of 
TEER, which gives a number to the tightness of the epithelium, and measuring the 
permeability of tracer molecules transported only via the paracellular route [119]. 
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For the bronchial cell line Calu-3 it could be shown, that when grown under LCC 
conditions or at the ALI cells develop barrier properties in vitro of >300 Ω*cm² [139]. 
This number of transepithelial electrical resistance should be reached to use such 
models for drug transport studies [104]. 
To evaluate the ability of both cell lines considered for the co-culture model to exhibit 
barrier properties when grown under different culture conditions (LCC or ALI), the cells 
were seeded on Transwell® plates as described under 3.2.1. TEER values were then 
measured every 2-3 days. As expected Calu-3 cells showed considerable barrier 
function 7 days after seeding (Fig. 3.1) when grown under LCC (512 ± 39 Ω*cm²) or at 
the ALI (324 ± 20 Ω*cm²). TEER values increased further and barrier properties were 
highest between day 9 and 12 after seeding, 1208 ± 63 Ω*cm² on day 12 for LCC 
cultures. Barrier properties for cells grown at the ALI although lower than the LCC 
cultures still reached with 742 ± 17 Ω*cm² considerable TEER values 12 days after 
seeding. Therefore, for further experiments (e.g., drug transport studies or infection 
with P. aeruginosa) cells were used between days 9-12 after seeding. After longer 
culture times TEER values decreased again, as shown in Figure 3.1 with the unfilled 
symbols (to give a trend preliminary data from 1 experiment was used). Differences in 
TEER values depending on the culture conditions were already described in a number of 
studies [139-141] but absolute values differ from lab to lab and have to be determined 
for the cells at hand. 
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Figure 3.1: Barrier properties of Calu-3. Cells were cultivated under LCC (red) or at the ALI 
(blue) conditions. The TEER values were measured every 2-3 days for up to 14 days. Data 
shown are mean ± SEM (n≥6) from at least two independent experiments. Unfilled symbols are 
from one experiment and give a trend. 
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The CFBE41o- cells reached their peak in TEER when grown under LCC already on day 7 
after seeding with 1475 ± 53 Ω*cm² (Fig. 3.2.) Afterwards values decreased again but 
still remained well above 600 Ω*cm². In contrast the cells cultivated at the ALI 
expressed highest barrier properties between day 5 and 6 with 271 ± 13 Ω*cm² on 
day 5. Later on TEER values fluctuated around 200 Ω*cm². Similar to the findings of 
Ehrhardt et al. [108] the ALI cultures did not reach considerable barrier properties to 
make them suitable for further experiments (e.g., infection with pathogens). 
Of note, the lower TEER values of both Calu-3 and CFBE41o- cells when grown at ALI 
might to some part be related to stress. In order to measure TEER, cells had to be 
incubated with culture medium, and after the measurement restored to ALI conditions 
(see 3.2.2). The mechanical stress related to the medium change (e.g., shear, 
hydrostatic pressure change) might also be a reason for the lower TEER values observed 
in cells cultivated at ALI. 
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Figure 3.2: Barrier properties of CFBE41o- cells. Cells were cultivated under LCC (red) or at ALI 
(blue) conditions. The TEER values were measured every 2-3 days for up to 19 days. Data 
shown are mean ± SEM (n≥8) from at least three independent experiments. 
  
Characterization and comparison of two human bronchial epithelial cell lines 
 
- 45 - 
3.3.2 CFBE41o- express a tight pattern of occluding only when cultivated under liquid-
covered conditions (LCC) 
To find an explanation for the lower TEER values in the ALI cultures a staining of TJ 
proteins was conducted. Since occludin is a key player in transepithelial electrical 
barrier function [126] and is nowadays considered as regulator of TJ assembly and 
function in vitro [130, 132], this protein was stained and the expression of the same 
under different culture conditions (LCC ft. ALI) was compared (Fig. 3.3). The left image 
in Figure 3.3 shows a tight pattern of the occluding protein surrounding the under LCC 
cultivated cells (A). In contrast the ALI cultured cells (B) exhibit a rather diffuse pattern, 
indicating an inhomogeneous distribution of the TJ protein. This could explain the lower 
measured TEER values in the ALI cultures of the CFBE41o- cells. Similar findings were 
also made by Ehrhardt et al. [108]. In addition, they also stained other TJ associated 
proteins (e.g., ZO-1 and claudin-1) and found that also for these proteins the expression 
profile in the ALI cultures is irregular, whereas the stained TJ proteins in LCC cells show 
a regular appearance and can explain the higher TEER values measured in these 
cultures. 
 
 
 
Figure 3.3 Tight junction staining in CFBE41o- cells. CLSM images of CFBE41o- cells cultivated 
under LCC (A) or at the ALI (B) for 18 days before fixation. TJ protein occludin (red) and the 
cytoskeleton (green) were stained. Scale bar: 20 µm 
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3.3.3 Culture condition influences transcellular permeablilty in CFBE41o- cells but not 
in Calu-3 cells 
In order to also shed some light on the difference in drug transport depending on the 
applied culture conditions, permeability studies with the paracellular transported 
model drug NaFluo, which can easily be detected by fluorescence spectroscopy, were 
conducted. 
Since the paracellular route is guarded by the TJs and the here used NaFluo is primarily 
transported this way, TEER values and Papp values, both markers for the tightness of the 
epithelial barrier, should correlate. An inverse correlation between TEER and Papp of 
paracellular transported markers was reported in several studies [141-143]. However, 
no further decrease of Papp values was observed for Calu-3 cells that had already 
reached TEER values of 450 Ω*cm² [141], indicating that even higher TEER values did 
not influence the permeability of paracellular transported drugs any further.  This also 
holds true for the Calu-3 cells used in these studies. Even though TEER values in cells 
cultivated under LCC were higher than in cells cultivated at the ALI (see Figure 3.1) Papp 
values did not differ significantly from one another (Figure 3.4). 
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Figure 3.4 Permeability studies with Na-Fluorescein on Calu-3 and CFBE41o- cells. Cells were 
cultivated under LCC (red) or at the ALI (blue) for 10 (Calu-3) or 5 days (CFBE41o-) before 
transport study was conducted. Data shown are mean ± SEM (n ≥ 12) from two (Calu-3) or 
three (CFBE41o-) independent experiments. * p < 0.05  
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In contrast, the CFBE41o- cells, which did not reach considerable barrier properties 
with ALI conditions (Figure 3.2), also showed a significant difference in Papp values 
(Figure 3.4). This illustrates that low TEER values result in an increased permeability of 
the cell monolayer and therefore an increase in Papp values. This emphasizes the fact 
that the CFBE41o- cells cultivated at the ALI are not suitable for additional experiments 
(e.g., use as cell line for infected CF model) without improvement of the ALI cultures 
that could alter TEER values and therefore the cellular barrier properties. 
Another aspect that comes to mind is that the measured Papp values of the Calu-3 cells 
are in general a little lower than for the CFBE41o- cells. This is no surprise for the cells 
that were cultivated at the ALI. CFBE41o- cells did not reach considerable barrier 
properties under these conditions. But cells that were grown under LCC showed higher 
TEER values on their peak than the Calu-3 cells. Even though Papp values differ from cell 
line to cell line and can still differ slightly from laboratory to laboratory even if the 
same cell line was used, they are usually in the same range [139-141, 143-146]. Thus, 
the observed differences in Papp values between CFBE41o- and Calu-3 cells could also be 
a hint to another barrier that plays a major role in the lung: mucus. 
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3.3.4 Calu-3 cells produce mucus when cultivated at the air-liquid interface whereas 
CFBE41o- cells lack mucus production 
Mucus serves primarily as a cytoprotective layer for most surfaces in the body. 
Especially epithelial cells are often covered with this viscous endogenous hydrogel 
composed of gel-forming mucins [147, 148]. To replenish the gel-layer these mucin 
glycoproteins are continuously synthesized and secreted by mucous cells in the 
gastrointestinal tract, the genitourinary tract, the ocular surface, the middle ear, as well 
as in the pulmonary airways. In the lungs the mucus gel is continuously propelled 
toward the trachea by ciliary beating, thus clearing inhaled pathogens and particles 
from the airways in a relatively short period of time [21, 149-151]. These protective 
barrier properties of mucus have to be taken into account, namely when thinking about 
therapeutic drug carriers such as nanoparticles (NPs) intended for pulmonary drug 
delivery, since they might impose a significant challenge for them [149, 152]. 
Since mucus would protect the cells from a presumable infection, but simultaneously 
presents a drug delivery barrier for the applied NPs, it was mandatory to investigate if 
the cell lines used in this work are able to produce mucus.  
Typically, acridine orange (AO) is used to stain cells and mucoglycoproteins for 
fluorescence spectroscopy. Using the pH sensitivity of AO and taking into account that 
mucus has acidic properties, this staining results in a green fluorescence for neutral cell 
compartments (cytoplasma) and a shift to red emission for the sour mucoglycoproteins 
[125]. In histology the PAS reagent is commonly used to stain glycoproteins, glycogen, 
polysaccharides and mucins [153] such as neutral mucopolysaccarides, while the dye 
Alcian blue is used to detect sour mucosubstances. In combination this allows to 
distinguish between neutral and sour mucins in one sample. In addition, scanning 
electron microscopy can be applied to image the cell surface, which allows to detect 
mucin fibers on top of the cells if present. All three techniques were used in this study. 
For Calu-3 cells it was shown that they express typical gens for mucus-secreting cells 
(e.g., MUC1, MUC2, MUC4, MUC5) [154, 155]. Mucus secretion is also depended on the 
used culture condition and can be enhanced when cells are cultivated at ALI [139]. The 
majority of studies even report that Calu-3 cells only produce mucus when exposed to 
air [139, 140, 146, 156]. However, some studies also report the production of mucus 
under LCC conditions [157, 158]. 
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Calu- 3 cells used in this study revealed an increased mucus production when grown at 
ALI conditions. When sour mucins were stained with AO just small amounts of mucus 
could be detected in the LCC culture (Figure 3.5 A), whereas the cells cultivated at ALI 
showed more sour mucins on the cell surface (Figure 3.5 B), evident by higher amounts 
of red emission. 
 
 
 
Figure 3.5 Acridine orange staining of Calu-3 cells. CLSM images of Calu-3 cultures. Cells were 
cultivated under LCC (A) or at the ALI (B) for 18 days before staining. The cytoplasm shows a 
green emission, while the sour mucins exhibit a red emission. Scale bar: 50  µm 
 
Similar results were obtained when mucus was stained with PAS/Alcian blue. Here as 
well, cells cultivated at ALI conditions (Figure 3.6 B) showed high amounts of sour 
mucins (blue colour), as well as high evidence of neutral mucins (pink colour). On the 
other hand, on top of the cells that were covered with liquid during cultivation just 
neutral mucins could be detected (Figure 3.6 A).  
Since mucus has a cytoprotective role and ALI conditions expose the cells to more 
stress, the increased mucus production can be a cellular response to the cultivation at 
these conditions. On the other hand, mucus production might be similar under 
submerged conditions. However, the produced mucins might dissolve in the overlaying 
liquid and are removed with medium change. Grainger et al. made similar observations 
regarding mucus production and also concluded the culture medium exchange as 
possible removal of secreted mucus [139]. Since it could be shown that Calu-3 cells, 
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grown in tissue culture flasks (LCC conditions) express MUC5/5AC mRNA and secrete 
this mucin in the surrounding medium [155], this seems a likely explanation. 
 
 
 
Figure 3.6 PAS/Alcian blue staining of Calu-3 cells. Light microscopy images of Calu-3 cells 
cultivated under LCC (A) or at the ALI (B) were taken after staining with periodic acid-Schiff 
(PAS) for neutral mucins and Alcian blue for sour mucins. More mucins are present when cells 
are cultivated at ALI. Small inserts in top left corner show unstained control of cells. Scale bar: 
200 µm 
 
In the SEM images of the Calu-3 cells the structure of the monolayer becomes evident. 
Cell boundaries are visible (Figure 3.7). Cracks in the cell layer are due to sample 
preparation. Long mucin fibers (strand like structures) can be seen on the surface 
spanning over several cells. But as already seen with AO and PAS/Alcian blue staining, 
mucus is more evident in ALI cultivated cells (e.g., more mucin fibers in Figure 3.7 B). Of 
note are the apical cell protrusions covering almost all cells in both images 
(Figure 3.7 A, B). However, it remains to be investigated, if these structures are indeed 
cilia, typical for primary airway cell cultures. Reports from several studies with Calu-3 
cells hold opposing views regarding this cell organelle. Some groups describe these 
structures as cilia [142, 156-158], while others report them as microvilli [139, 143, 144, 
154, 159] indicating that this is still a matter worth investigating. 
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Figure 3.7 Morphology of Calu-3 cells. SEM images of Calu-3 cells cultivated under LCC (A) or 
at the ALI (B) were taken. Under both conditions mucin fibers are evident on top of the cells. 
Microvilli on the cell surface are present under both culture conditions. Scale bar: 20 µm top 
pictures and 5 µM bottom pictures. 
 
CFBE41o- cells, though not as widely used as Calu-3 cells, are also already very well 
described in the literature. However, reports on mucus productions are scarce and 
were therefore conducted with the above-mentioned techniques. 
Similar to the Calu-3 cells the AO staining showed more sour mucins (red emission) 
when cells were cultivated at ALI (Figure 3.8 B). LCC cultured cells just showed sporadic 
red emission (Figure 3.8 B), indicating a reduced mucus production or removal due to 
media exchange much like the Calu-3 cells. However, PAS/Alcian blue staining of the 
CFBE41o- cells cultivated submerged show small amounts of neutral mucins 
(Figure 3.10 A, pink stained secretions on top of the cells), whilst the air exposed cells 
show no evidence of mucus production at all (Figure 3.9 B). This stands in contrast to 
the Calu-3 cell line, where ALI condition massively increased the mucus production. On 
the other hand, this is in agreement with the findings of Moreau-Marquis et al. and 
Price et al. who also found that CFBE41o- cells do not produce mucus [160, 161]. 
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Figure 3.8 Acridine orange staining of CFBE41o- cells. CLSM images of CFBE41o- cultures. Cells 
were cultivated under LCC (A) or at the ALI (B) for 18 days before staining. The cytoplasma 
shows a green emission, while the sour mucins exhibit a red emission. Scale bar: 50 µm 
 
To exclude that the lack in mucus production results from a shorter cultivation time at 
ALI conditions (5 days for CFBE41o- cells in contrast to 10 days for Calu-3), cells were 
cultivated for up to 10 days at ALI conditions and PAS/Alcian blue staining was 
repeated. But results remained the same (data not shown). No secretion of mucus 
could be detected in CFBE41o- cells, irrespective of culture condition and culture time. 
 
 
 
Figure 3.9 PAS/Alcian blue staining of CFBE41o- cells. Light microscopy images of CFBE41o- 
cells cultivated under LCC (A) or at the ALI (B) were taken after staining with periodic acid-
Schiff (PAS) for neutral mucins and Alcian blue for sour mucins. Only a couple of neutral mucins 
are detected in the LCC culture, while no mucins are evident in ALI sample. Small inserts in top 
left corner show unstained control of cells. Scale bar: 200 µm 
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To further confirm the lacking mucus production in this cell line, but also get some 
additional insight on the morphology of those cells SEM images were taken. Cell 
monolayers of cells with clearly visible boundaries can be seen in Figure 3.10 (top row). 
In the enlargement of Figure 3.10 A the LCC grown cells exhibit apical cell protrusions 
similar to the Calu-3 cells under the same conditions. Even more prominent are the 
microvilli-like structures in the bottom image of Figure 3.10 B. The ALI cultured cells 
exhibit these structures in different length on individual cells. The long filaments in this 
enlargement of CFBE41o- cells might even resemble cilia. Nonetheless, no mucin fibers 
could be detected on either of the samples. This contributes to the fact that the 
CFBE41o- cells indeed lack mucus secretion. Since these cells are of bronchial origin 
obtained from a CF patient and should therefore be able to secret mucins, they might 
have lost this ability during the immortalization process with the simian virus (SV40) 
[107]. 
 
 
 
Figure 3.10 Morphology of CFBE41o- cells. Scanning electron microscopy images of CFBE41o- 
cells cultivated under LCC (A) or at the ALI (B) were taken. No evidence of mucin fibers could be 
detected. Microvilli in different length on the cell surface are present under both culture 
conditions. Scale bar: 20 µm top pictures and 5 µM bottom pictures.  
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3.4 Conclusion 
SEM images of Calu-3 and CFBE41o- cells confirm that both cell lines form monolayers 
when seeded onto Transwell® filters. While Calu-3 cells exhibit high TEER values when 
grown under both LCC and at ALI conditions, CFBE41o- cells only show considerable 
barrier properties when grown under submerged conditions. CLSM images showed a 
diffuse pattern of the tight junction protein occludin in ALI cultures of CFBE41o- cells. 
This could explain the difference in TEER values observed under different culture 
conditions in this cell line.  
The permeability of a paracellular transported model drug NaFluo was significantly 
different in CFBE41o- cells depending on the applied culture condition. Even though 
TEER values in Calu- 3 cells differed in height depending on the growth conditions, no 
significant effect on the Papp was observed in this cell line. 
With AO, PAS/ Alcian blue staining and SEM images it could be shown that Calu-3 cells 
produce mucus under both LCC and ALI conditions but secretion of mucus is drastically 
increased when cells were grown exposed to air.  
While the AO staining gave the impression that also CFBE41o- cells exhibit an increased 
mucus production when grown at ALI, SEM images and the PAS/alcian blue staining 
actually showed that these cells lack mucus production irrespective of the used culture 
condition. 
To conclude from the presented results only the Calu-3 cell line has potential to be 
used at ALI in further studies, for example for drug deposition with the Pharmaceutical 
Aerosol Deposition Device On Cell Cultures (PADDOC) [110, 162] or infection with 
P. aeruginosa. In order to also use the cystic fibrosis cell line at ALI conditions in such 
experiments their barrier properties and TEER values need to be improved. One 
possibility could be to supply those cells with an external mucus layer to increase those 
parameters and adapt permeability to that of LCC grown cells. 
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4 Alternatives to mucus produced by the cell line 
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4.1 Introduction 
Mucus has numerous functions, but especially in the lungs it serves as barrier to 
prevent inhaled pathogens and pollutants but also therapeutic NPs from entering the 
underlying cells [163]. But mucus also hydrates the airways and has antioxidant, 
antimicrobial and antiprotease activities [164]. In CF thick and sticky pulmonary mucus 
presents a major hallmark of the disease, leading to airway obstruction, inflammation 
and infection, which in turn are the cause for morbidity and mortality in patients 
suffering from CF [57, 58]. 
Given, that mucus plays a major role as a barrier that needs to be considered when 
thinking about drug delivery to mucus producing organs (e.g., gastrointestinal tract, 
lung, eye), the development of mucus models has gained more and more attention. 
They can be useful tools to mimic this barrier and study drug diffusion.  
In view of the fact that the CFBE41o- cells used in this study are unable to produce 
mucus, but are otherwise well suited for the in vitro co-culture model, since they are 
derived from a CF patient and are homozygous for the most common mutation in CF, 
the supplementation of the cells with an external mucus layer to achieve a more in vivo 
like model was therefore the obvious solution. Besides, this opened up the opportunity 
to use different mucus sources for the in vitro model. 
Numerous models of mucus are described in the literature ranging from simple ex vivo 
to complex in vivo models. Application of plain mucins, artificial mucus compositions, to 
native mucus from horse, pig, cow or human have been described. It is even possible to 
use pathologic mucus to better mimic certain diseases such as CF [165]. 
The fact that pigs have a similar anatomy in respect to lung size, physiology, 
metabolism, and pathology to humans and in addition have a longer lifespan compared 
to rodents, makes the pig a valuable species for models of human lung diseases [166-
168] and to acquire mucus from. 
To model the mucus barrier in the lung a lot of published studies use a commercially 
available porcine gastric mucin [163, 169], relate to freshly isolated gastric mucins 
[170], create their own artificial mucus [147, 171], or use native mucus isolated from 
animals [172] or humans [147, 173]. In a lot of cases the source organ differed from the 
mimicked model organ (e.g., artificial mucus with porcine gastric mucin for CF 
mucus) [171]. 
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Even though the exact source of mucus might not be of importance to study interaction 
and penetration of drug delivery systems such as NPs, airway mucus (i.e., pulmonary 
porcine mucus and endotracheal human mucus) was used for these studies. It could be 
shown that the major two human airway mucin glycoproteins, the mucins MUC5AC and 
MUC5B, are present in pig lung as well [166]. Rheological properties of the airway 
porcine mucus used are typical for cross-linked gels and similar to human tracheal 
mucus [149]. To go even further one could use the mucus of genetically engineered pigs 
with cystic fibrosis, as it was shown that they develop typical hallmark features of CF 
like airway inflammation, mucus accumulation, and infection [174]. 
Even though porcine mucus is very similar to the human mucus, the human one should 
be favored as external mucus supply for the CFBE41o- cells. Nonetheless, the supply of 
human mucus is even more difficult than that of porcine airway mucus. With access to 
CF mucus one could even further improve the here described in vitro model. But to 
proof the hypothesis, that the low TEER values and questionable barrier properties of 
the CFBE41o- cells could be improved, we related to the above mentioned porcine 
airway mucus and human mucus (obtained via endotracheal tube method) from healthy 
donors.  
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4.2 Material and methods 
4.2.1 Pulmonary porcine mucus 
Pulmonary porcine mucus was collected from pig tracheas as described in Murgia et al. 
[149]. Briefly, tracheas of slaughtered pigs were cut below larynx and before carina 
resulting in a 10 cm long section of the windpipe. Tracheas were stored on ice prior to 
mucus extraction. Tracheas were cut in half in a longitudinal direction (i.e., along the 
trachealis muscle) and mucus was carefully extracted with a spatula (100-300 µl of 
mucus sample per trachea). Samples were stored at -20°C and freeze dried afterwards, 
which led to a destruction of bacteria usually found in mucus. Furthermore, it allowed 
determining the mucin contents of the freeze-dried samples, thus, ensuring the use of 
equal amounts of mucus in all experiments. 
4.2.2 MTT assay 
To investigate if the CFBE41o- cells tolerate the porcine mucus at all, CFBE41o- cells 
were seeded in a 96 well plate with a density of 20,000 cells/well and grown until 
approximately 70% confluent (usually 2-3 days after seeding). Medium was then 
removed and cells incubated with 200 µl per well of mucus resuspended in KRB (in 
different concentrations e.g., 1 mg, 5 mg and 10 mg per ml). The viability of the cells 
was checked with an MTT assay 24 h after mucus application. The positive control 
(100% viability) being only KRB, whereas the negative control (0% viability) consisted of 
1% Triton X in KRB. After the 24 h incubation time, supernatants where removed, cells 
washed once with 200 µl KRB/well and then further incubated with 110 µl MTT solution 
(500 µg/ml MTT) for another 4 h. After that time 100 µl DMSO was added in each well 
to dissolve the developed formazan crystals. Absorption at 550 nm was measured with 
a plate reader (TECAN, infinite M200 pro, Männedorf, Switzerland). 
4.2.3 TEER measurements 
To evaluate the effect of mucus on the barrier properties, TEER values were measured 
every other day after mucus application on cells seeded on Transwells® as described 
under 3.2.3. To ensure that mucus would not be removed when ALI conditions were 
restored after measurement, excess medium was removed with a manual pipette.  
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4.2.4 Human mucus 
With the PAS/Alcian blue staining described under 3.2.6 it was confirmed that CFBE41o- 
cells do not produce mucus [160, 161]. But since mucus is a major component in a CF in 
vitro model the use of a mucus source is mandatory. Undiluted human mucus was 
obtained by the endotracheal tube method [173, 175-177]. This protocol was approved 
by the Ethics Commission of The Chamber of Medicine Doctors of the Saarland under 
the file number 19/15. The obtained mucus was stored at -20°C and gradually thawed 
and left to reach RT when needed. Single drops (weight approximately 30-40 mg each) 
of the thawed mucus were transferred to a Teflon® template with circular cavities. 
Mucus filled templates were then placed in an autoclavable sealing bag and stored at 
-80°C for 4 h. Subsequently, they were freeze-dried overnight (Alpha 2-4 LSC, Christ, 
Germany). After completing the freeze-drying course, the resulting mucus disks (with 
an estimated solid content of 1.7 ± 0.1 mg and 95% water content) were sealed in the 
autoclaving bag and stored until use at RT in a dry atmosphere. 
These mucus disks were then carefully removed from their template with tweezers and 
placed on top of CFBE41o- monolayers 5 days after seeding. Mucus disks were 
rehydrated with 50 µl of cell culture medium. The Transwell® plates with CFBE41o- cells 
and additional human mucus were then placed on a shaker platform inside an incubator 
(at 5% CO2 atmosphere and 37°C) and rotated at 150 rpm until the following day. This 
allowed an even distribution of the mucus over the cell monolayer. 
4.2.5 Statistical analysis 
Data are presented as mean ± standard error of the mean (SEM) from 2-3 independent 
experiments. Statistical analysis was performed with the GraphPad Prism 5 software. 
The differences in viability and TEER were compared with a Two-way ANOVA and a 
Bonferroni post test; * p < 0.05 and *** p < 0.001 were considered significant.  
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4.3 Results and Discussion 
4.3.1 Porcine mucus is well tolerated by CFBE41o- cells 
Since the CFBE41o- cells lack mucus and even a longer cultivation at ALI conditions led 
to no secretion of mucins, the application of an external mucus layer seemed 
appropriate. Thanks to a well-established collaboration with a regional slaughter house 
(in Zweibrücken, Germany) pulmonary porcine mucus was the first option for external 
mucus because of its unrestricted supply and similarity to human mucus [166]. The 
obtained mucus was freeze-dried and resupsended as needed. 
In order to ascertain that the freeze-dried pulmonary porcine mucus had no cytotoxic 
effects on the CFBE41o- cells, different amounts of mucus were applied onto the cells 
and the viability was checked with an MTT assay 24 h later (Figure 4.1). 
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Figure 4.1: Viability of CFBE41o- cells after porcine mucus application. Porcine mucus from 3 
different pigs was applied on the CFBE41o- cells. 24 h later an MTT assay was performed to 
measure the cell viability. Data shown are mean ± SEM (n=9) from three independent 
experiments. 
 
The applied mucus had no cytotoxic effect on the cells after 24 h. Similar results were 
reported by Teubl et al. [125]. They could show that applied porcine mucus (from 
stomach) had no impact on the mitochondrial activity of TR 146 cells, an oral epithelial 
cell line. Although variability between different donors (Pig 1-3) could be observed, it 
did not reach significance. Since MTT measures the mitochondrial activity of the cells 
an increase of viability over 100% (compared to the positive control; cell culture 
medium) in the samples from pig 1 and 2 for the concentration 5 mg/ml and 10 mg/ml, 
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respectively, could indicate that the cells activity is amplified, which can happen when 
cells are under stress. A longer incubation with mucus would clarify, if an actual 
cytotoxic effect is to be expected at a later stage from the applied mucus. But from the 
findings of Teubl et al. who had similar increased viability over 100% after 4 and 24  h 
but no cytotoxic effect after 48 h [125], we can presume that this is probably not the 
case. 
Even though long-term cytotoxicity remains to be investigated, the second highest 
mucus concentration (5 mg/ml) was chosen for further studies. This concentration 
might better resemble the clinical picture of CF, where the accumulation of thick mucus 
contributes massively to the development of chronic infections in CF, bearing in mind 
that mucus offers good growth conditions for bacteria.  
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4.3.2 Porcine mucus only increases TEER values of air-liquid interface cultivated 
CFBE41o- cells 
In general, cells in ALI show reduced barrier properties compared to the submerged 
culture (see chapter 3.3.2). When mucus (5 mg/ml) was applied to the ALI cultivated 
cells on day 5 after seeding, TEER values increased up to day seven and reached 
318 ± 87 Ω*cm², the difference in TEER between cells w/o porcine mucus 
(104 ± 13 Ω*cm²) being highly significant on that day (Figure 4.2). 
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Figure 4.2: Barrier properties of ALI cultured CFBE41o- cells after mucus application. Porcine 
mucus was applied on the CFBE41o- cells after TEER measurement on day 5 after seeding 
(green arrow). TEER was measured for up to 14 days after seeding. Data shown are mean 
± SEM (n≥5) from at least two independent experiments. *** p <0.001 
 
After that, barrier properties decreased again and on day 10 after seeding even 
dropped below values of cells that did not receive extra mucus (Figure 4.2). These cells 
however never reached considerable TEER values as described previously (Figure 3.2). 
Of note is that mucus alone did not show barrier properties (42 ± 11 Ω*cm², data not 
shown). This was assessed by measuring TEER values in cell free Transwells® that were 
supplemented with mucus in the same concentration as the mucus treated cells 
(5 mg/ml; data not shown). Thus, simple physical factors (e.g., clogging of the 
Transwell® pores by mucus) were not the reason for the increased TEER values 
observed on day seven after seeding. 
Why the increase of the cells barrier properties just lasted for a short amount of time 
remains to be investigated. One possible explanation is the removal of the applied 
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mucus with culture medium after TEER measurement. Even though this step was done 
very cautious, it cannot be avoided that some of the mucus dissolves in the medium 
and is thereby removed. If this is indeed the case or the increase of TEER values after 
mucus application is just temporary could be proved by a repeated application of 
porcine mucus and continuous TEER measurements. On the other hand, also a delayed 
cytotoxic effect of the porcine mucus might be a possible route cause for the 
decreasing TEER values after day 7. Since viability of the cells was just measured 24 h 
after mucus application (see chapter 4.3.1), also a later toxic potential of the porcine 
mucus might be a possible explanation. 
When mucus was applied to the submerged culture (Figure 4.3), TEER values decreased 
in comparison to the LCC cultured cells without porcine mucus (1631 ± 140 Ω*cm² for 
LCC versus 777 ± 140 Ω*cm² for LCC+mucus) In contrast to the ALI cultivated cells, the 
applied mucus seems to have a negative effect on the barrier properties of the 
CFBE41o- cells in this case. This observation even reached significance on day 7, 12 and 
14 after seeding. Similar adverse effects, where the exogenous porcine mucus even 
disrupts epithelial monolayer, were already reported. The group of Bough et al. 
observed a dramatic decrease of TEER values after porcine intestinal mucus was applied 
to Caco-2 cells [178]. 
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Figure 4.3: Barrier properties of LCC cultured CFBE41o- cells after mucus application. Porcine 
mucus was applied on the CFBE41o- cells after TEER measurement on day 5 after seeding 
(green arrow). TEER was measured for up to 14 days after seeding. Data shown are mean 
± SEM (n≥5) from at least two independent experiments. *** p <0.001; * p <0.05 
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Considering that porcine mucus is slightly different from human mucus after all and 
even decreases the TEER values of the LCC cultured cells, it appears that the addition of 
an external mucus layer only makes sense for ALI cultivated cells. Here it can be 
concluded that with the application on day 5 after seeding highest barrier properties 
can be expected on day 7 after seeding. The infection with bacteria as next step in the 
direction of a co-culture model should therefore be performed on that day, because 
high barrier properties likely increase the cellular resistance to the infection and favour 
the survival of the epithelial cells. 
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4.3.3 Human mucus increases TEER values of air-liquid interface cultivated CFBE41o- 
cells by 7-fold 
The addition of porcine airway mucus did not achieve the desired results of raising the 
TEER values of the CFBE41o- cells considerably (just about 300 Ω*cm² for one day, see 
Figure 4.2) but nevertheless an increasing effect could be observed on the ALI 
cultivated cells. However, this effect did not last. Besides, LLC cultivated cells even 
showed decreasing TEER values. This was in agreement with previous studies, which 
showed similar adverse effects (e.g., disruption of barrier properties and cytotoxicity) 
when porcine mucus was applied on epithelial cells [125, 178]. 
Nevertheless, we hypothesized that due to same mutual human origin CFBE41o- cells 
and human airway mucus might accomplish better results. Therefore, further 
experiments with human mucus were conducted. 
First evaluations concerning cytotoxicity and rheological behavior of human airway 
mucus were already performed by Murgia et al. [177]. They found, similar to the 
porcine mucus, a slightly increased viability after 24 h compared to the control cells. 
This might even suggest a positive effect of mucus on the CFBE41o- cells. They 
confirmed the compatibility of the exogenous human mucus with the epithelial cells 
even further through a live dead staining, finding a high cell viability in mucus 
incubated cells. When they applied the mucus to LCC cultured CFBE41o- cells, TEER was 
slightly increased, although values did not reach significance [177].Reassured by those 
observation the freeze-dried human mucus was thus applied on the ALI cultivated 
CFBE41o- cells on day 5 after seeding and indeed, human mucus raised the TEER values 
of the ALI cultivated CFBE41o- cells notably in contrast to porcine mucus (Figure 4.4). 
Barrier properties increased by 7-fold (230 ± 20 Ω*cm² without mucus versus 
1573 ± 126 Ω*cm² for cells with mucus). Human mucus alone (cell-free Transwell® with 
mucus) only reached 21 ± 8 Ω*cm². Thus, the applied mucus does not create a physical 
barrier (e.g., by clogging of the Transwell® pores). Therefore, a synergistic effect, and 
not an additive one, must be causing the higher TEER values observed after mucus 
application. 
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Figure 4.4: Barrier properties of ALI cultured CFBE41o- cells after human mucus application. 
Human mucus was applied on the CFBE41o- cells on day 5 after seeding (green checkered). 
TEER was measured on day 7 after seeding. Data shown are mean ± SEM (n≥18) from at least 3 
independent experiments (only mucus; n=4 from two independent experiments). *** p <0.001. 
 
Of note is also, that no bacterial contamination was detected when freeze-dried human 
mucus was used. Since mucus contains bacteria even in healthy state, the freeze-drying 
process probably reduced the bacterial load of the exogenous human material [177]. 
That the freeze-drying procedure had no effect on the rheological properties of mucus 
was confirmed in the study by Murgia et al. They showed that the freeze-dried and re-
suspended mucus had a comparable rheological behavior to the undiluted native mucus  
and behaved as a semi-permeable layer, indicating that this mucus offers the additional 
mucus barrier the CFBE41o- cells are still lacking [177].  
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4.4 Conclusion 
CFBE41o- cells do not produce mucus, a key cytoprotective element found in the lung. 
But apart from that, they offer valuable features such as the expression of TJ proteins 
and proteins relevant for pulmonary drug transport and in addition a shorter cultivation 
time compared to Calu-3. For those reasons the aim was to improve this cell line with 
exogenous mucus to use it for the co-culture model. Two external mucus sources were 
evaluated: porcine airway mucus and human airway mucus.  
Both mucus sources proved to be non-cytotoxic to the cells as seen by the high viability 
of the CFBE41o- cells after 24 h incubation with either form of mucus. 
Meanwhile, the effect on the barrier properties of the epithelial cells was quite diverse. 
Porcine mucus decreased TEER values of LCC cultivated cells significant , but on the 
other hand could slightly improve barrier properties of ALI cultivated cells for a short 
time period. 
In contrast, human mucus increased TEER values of ALI cultivated CFBE41o- cells 
significantly over 300 Ω*cm² regarded as the threshold value to present a tight barrier. 
This positive effect on the CFBE41o- cells can probably be explained by the common 
human origin of both cell line and mucus and was therefore favoured over the porcine 
mucus. The disc-like form of the human mucus achieved through freeze-drying on a 
template makes it easy to apply to the cell culture. In addition, the microbiological 
burden was reduced in the course of the freeze-drying process avoiding bacterial 
contamination by the exogenous human material. 
Further studies on rheology of the freeze-dried human mucus and uptake studies with 
NP of different size by Murgia et al. [177] proofed that this human airway mucus is 
indeed a perfect option to supplement the non-mucus producing CFBE41o- cells with a 
mucus layer. Thus, by introducing human mucus, a protective element to the epithelial 
cell monolayer, and at the same time another important biological barrier could be 
added to the in vitro model. 
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formation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The author of the thesis made the following contribution to this chapter: 
Planned and performed all bacterial experiments, measured OD600, stained and 
quantified crystal violet assays, analyzed and interpreted all obtain experimental data 
and wrote the chapter. 
  
Cultivating Pseudomonas aeruginosa and optimizing biofilm formation 
 
- 69 - 
5.1 Introduction 
Pseudomonas aeruginosa is the most common pathogen in adult CF patients [41]. By 
late adolescence the majority of patients suffering from this genetic disease is infected 
with it [25, 26]. This Gram-negative bacterium uses its flagella and type IV pili to swim 
in media and move on solid surfaces by means of reversible flagella rotation and 
twitching motility, respectively [179]. In addition, the flagella of P. aeruginosa play an 
important role in biofilm formation. It has been shown that P. aeruginosas flagella 
contribute to the initial colonization by means of mucin-adhesion, and thus to the start 
of biofilm formation [180]. 
P. aeruginosa’s ability to build biofilms and the resulting resistance against common 
antibiotic therapy, qualifies this pathogen as model organism in our CF co-culture 
model, and thus test the efficacy of novel drug delivery systems against chronic 
infections in CF caused by this pathogen. 
Since the development and presence of a biofilm is cause for the failure of current 
treatment therapies, mimicking the same in our model was crucial. Given that biofilm 
development needs time and is dependent on a lot of parameters [181], the aim was to 
find the optimal growth conditions for P. aeruginosa to develop a biofilm in vitro. In 
view of the fact that bacteria can respond to nutrient conditions very rapidly, the 
contents of the growth medium are essential for their regulation of biofilm formation 
[182-184]. As culture medium usually a minimal medium like M63 [185], supplemented 
with different carbon and energy sources, is to be favored. Such a medium facilitates 
biofilm formation in P. aeruginosa [186]. Studies from O’Toole et al. showed that LB 
medium or M63 supplemented with either glucose, glycerol, citrate, lactate, glutamate, 
succinate, gluconate or casamino acids would promote biofilm formation [186] and first 
microcolony formation can already be detected after 3 h [160]. Also the combination of 
a carbon source (mostly glucose) and casamino acids is widely used. Furthermore, 
Caiazza et al. found that the addition of arginine to the minimal medium M63 as sole 
carbon and energy source results in enhanced biofilm formation [187]. Therefore, the 
aim was to try those different supplements to the M63 alone or in combination, in 
order to find the best conditions for the strain used in these studies: P. aeruginosa 
PAO1. 
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The P. aeruginosa strain PAO1 was originally isolated from a burn wound in 1955 [188]. 
It is a widely used laboratory strain and also the first Pseudomonas species with a 
complete sequenced genome [189]. Around 770 articles have been published in the last 
5 years alone, as listed on the NCBI PubMed database [190], using this specific 
P. aeruginosa strain. About 15% of these studies are related to CF research. Several 
studies compared clinical CF isolates to the model strain PAO1. Penesyan et al. found, 
that even though PAO1 and the clinical isolates had a high similarity in their proteome, 
they significantly differed in their metabolism and physiology [191]. However, 
Jørgensen et al. found just small changes in respiratory reduction when comparing 
PAO1 to early lung isolated strains of CF patients [192]. In addition, one has to consider 
the high diversity found in clinical isolates from CF patients. The four isolates compared 
in the studies of Penesyan et al. differed among other things in colony morphology, 
type of flagella, swimming motility and their ability to form a biofilm. One of the strains 
analyzed was not able to build a biofilm. Also their ability to bind to mucins, and the 
production of certain virulence factors (e.g., phenazine, pyoverdine) was very diverse 
[191]. These substantial phenotypic differences between the clinical isolates make it 
extremely difficult to select just one strain for an in vitro model. 
So despite the observed differences to clinical isolates, PAO1 shows a lot of traits that 
are important for lung colonization as it is found in CF patients (e.g., flagella expression 
and medium binding to mucins, biofilm formation, production of virulence factors) 
[191]. Thus, PAO1 was used as model strain in this work. However, in future the use of 
clinical isolates, that do not lack biofilm formation, might be an option. 
The initiation of biofilm development can occur on biotic (e.g., human cells) and abiotic 
(e.g., plastic cell culture dishes) surfaces likewise. Therefore, a useful tool to indirectly 
monitor the biofilm development is staining with crystal violet (CV) [183]. This purple 
dye stains the bacteria and biofilm, but not the plastic of the culture dishes. The 
amount of biofilm formation can be quantified by solubilizing the biofilm associated 
dye and determining its absorbance at 600 nm [186].  
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5.2 Material and Methods 
5.2.1 Overnight cultures 
To obtain overnight cultures in which the bacteria, P. aeruginosa strain PAO1 and a 
fluorescent labelled PAO1 strain (ATCC® 10145GFP™), are in exponential growth phase, 
one colony was picked with a sterile pipette tip from an agar plate containing the 
desired bacteria and the colony was transferred in 10 ml sterile LB broth (Sigma-
Aldrich, Munich, Germany) supplemented with necessary antibiotics for the GFP 
labelled strain (300 µg/ml ampicillin; Carl Roth, Karlsruhe, Germany). Inoculated broth 
was incubated for 16-18 hours at 37°C and 180 rpm. 
5.2.2 OD600 measurements 
Overnight cultures were centrifuged at 1250 g and supernatant was discarded. The 
bacterial pellet was then resuspended in 10 ml sterile PBS. Optical density at 600 nm 
(OD600) of the bacterial solution was measured with a plate reader (TECAN, infinite 
M200 pro, Männedorf, Switzerland). Concentration of the bacterial solution was 
adjusted to achieve an OD600 ~ 0.1. 
5.2.3 Medium optimization for biofilm formation 
With the aim to find the optimal medium composition to grow P. aeruginosa PAO1 
biofilms, different supplements to the minimal growth medium M63 (1 l of medium 
contained: 13.6 g of KH2PO4, 2 g of (NH4)2SO4, 0.5 mg FeSO4, 1 mM MgSO4⋅7H2O) [193, 
194] were evaluated. Single use or combinations of a carbon source (e.g., 0.2% of 
glucose or glycerol), casamino acids (Sigma Aldrich, 0.5%) and/or arginine (Sigma 
Aldrich, 0.4%) were examined. Thus, overnight cultures of P. aeruginosa PAO1 were 
prepared as described under 5.2.1 and diluted 1:50 (OD600 of ~ 0.1) in the different 
media compositions adapted from the protocol of O’Toole [100]. To allow biofilm 
formation, 100 µl of each inoculated medium was transferred in a 96-well plate 
(4 replicates each) and incubated for 24 h at 37°C under static conditions. After the 
incubation time, the supernatants were removed and the resulting biofilms stained 
with crystal violet. 
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5.2.4 Biofilm staining with crystal violet 
To stain the resulting biofilm and quantify its mass, a crystal violet (CV) staining was 
conducted as described by O’Toole [100, 186]. Briefly, supernatant of each well was 
discarded and the plate rinsed two times with water to remove unattached and 
planktonic bacteria. Hereafter, 125 µl of a 0.1% CV solution was added in each well and 
incubated for 12 min. After that time the CV solution was removed and plate rinsed 3 
times with water and then left to dry. Staining was dissolved by adding 125 µl of 
ethanol 96% for another 12 min under gentle shaking. From each well 100 µl were 
transferred to a new plate and absorption at 600 nm was measured with a plate reader. 
Higher absorption values are an indicator for a larger biofilm mass that was stained. 
5.2.5 Statistical analysis 
Data are presented as mean ± standard error of the mean (SEM) from 4 independent 
experiments (n=16) for the medium addition to M63 and 4 independent experiments 
(n=12) for the combination of supplements. Statistical analysis was performed with the 
GraphPad Prism 5 software. The differences in absorption were compared with a One-
way ANOVA and a Bonferroni post test; * p < 0.05 and *** p < 0.001 were considered 
significant.  
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5.3 Results and Discussion 
5.3.1 Arginine as supplement in minimal bacterial growth medium M63 shows best 
results in enhancing P. aeruginosa biofilm formation 
In order to enhance P. aeruginosa PAO1 biofilm formation, different supplements were 
added to the minimal medium M63. The resulting biofilms attached to the assay plate 
were stained with CV, solubilised and quantified. The minimal medium M63 alone 
almost did not allow for any biofilm formation (A600 = 0.0436 ± 0.0052; Figure 5.1, white 
bar). Also the addition of the energy source glucose (medium grey bar in Figure 5.1) had 
no effect on biofilm formation. This stands in contrast to the findings of O’Toole et al. 
[183] who reported that glucose alone promotes biofilm formation. Although one has 
to keep in mind that their experiments were performed with Pseudomonas fluorescens, 
which might behave slightly different then P. aeruginosa. 
On the other hand, the addition of arginine to the medium enhanced the resulting 
biofilm mass significantly by 17-fold (A600 = 0.7290 ± 0.0339, Figure 5.1, light grey bar). 
Furthermore, also glycerol and casamino acids showed significant increase in biofilm 
formation (dark grey and black bar in Figure 5.1, respectively), but not to the extent of 
arginine. Similar results for P. aeruginosa were also reported by Caiazza et al. [187]. 
They found that bacteria grown in arginine enriched M63 medium or LB showed a 
robust biofilm formation, while glucose as supplement only resulted in a weak biofilm. 
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Figure 5.1: Biofilm development of P. aeruginosa in enriched M63 media. Bacteria were 
inoculated for 24 h with M63 enriched with different supplements. Biofilms were stained with 
CV and quantified. Data shown are mean ± SEM (n=16) from four independent experiments. 
*** p <0.001; * p <0.05. 
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However, intermediate levels of biofilm formation were observed, when glucose and 
CAA were both added to the medium. Also several other studies use a combination of 
glucose and CAA as M63 supplements to study biofilm formation. Thus, the mixture of 
arginine, glucose or glycerol with CAA was tested in order to find out if biofilm 
formation could be further enhanced (Figure 5.2). 
As hypothesised, the addition of CAA to glucose or glycerol enriched M63 medium 
enhanced P. aeruginosa biofilm formation significantly by 7-fold and 3-fold, 
respectively (medium and dark grey bars in Figure 5.2). But this is probably just an 
additive effect of both components together. Surprisingly, for the arginine minimal 
medium this effect was not observed. Even though measured absorption was slightly 
higher when a combination of arginine and CAA was used as culture medium, values did 
not reach significance (light grey bar in Figure 5.2). But since both components are 
amino acids, a mixture of both might not trigger further biofilm formation in 
P. aeruginosa. Even though the combination of supplements could achieve a higher 
biofilm mass in two cases, arginine as sole addition to the minimal medium M63 
offered the best results for the here used strain PAO1. Consequently, this media 
composition was used for all further studies with P. aeruginosa PAO1, where biofilm 
formation was desired. 
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Figure 5.2: Biofilm development of P. aeruginosa in M63 media enriched with combination of 
supplements. Bacteria were inoculated for 24 h with M63 enriched with different supplements. 
Biofilms were stained with CV and quantified. Data shown are mean ± SEM (n=12) from three 
independent experiments. *** p <0.001; ns = not significant. 
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Of note, Anderson et al. found that this media composition not only enhances 
P. aeruginosa biofilm formation, but also delays the killing of the epithelial cells, thus, 
allowing biofilm formation on an intact monolayer of CFBE41o- cells [112]. However, in 
their co-culture model consisting of CFBE41o- cells, grown under submerged conditions, 
and P. aeruginosa PA14, monolayer integrity was preserved for up to 9 h. If the same 
conditions in the model of ALI cultivated CFBE41o- cells and P. aeruginosa PAO1 would 
allow for sufficient biofilm formation in order to test the efficacy of the novel drug 
delivery system (DDS) was to be investigated.  
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5.4 Conclusion 
In order to find the best media composition for P. aeruginosa PAO1 to form a biofilm, 
different supplements and combinations of them were evaluated. Even though 
combinations of a carbon and energy source (e.g., glucose or glycerol) with casamino 
acids showed enhanced biofilm formation in contrast to the sole energy source, the 
addition of arginine as only supplement to the minimal medium M63 offered the best 
results in promoting the biofilm formation. In addition, it was shown that arginine also 
preserves the monolayer integrity of epithelial cells [112], thus, offering two benefits in 
one. No further improvement was achieved when arginine and CAA were combined 
hence, making arginine as sole supplement to the M63 medium the best option for 
these studies. Since first biofilm formation can be observed only after 3 h further 
analysis is necessary in order to see, if these condition are favourable enough to allow a 
biofilm formation on a viable epithelial cell monolayer, and permit a subsequent 
application of drug loaded NPs for their evaluation. 
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6 Co-culture of human bronchial epithelial cells and 
P. aeruginosa PAO1 
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6.1 Introduction 
Co-cultures of human epithelial cells and bacteria to mimic the infection with 
pathogens in cystic fibrosis patients have already been described. Especially the 
infection with P. aeruginosa and the formation of an antibiotic resistant biofilm on top 
of epithelial cells are of great interest, since this situation will overtake in almost all CF 
patients rather sooner than later. Due to the lack of adequate treatment these 
infections become chronic and further enhance the endobronchial inflammation and 
tissue destruction in the lung, leading to decrease in pulmonary function and inevitable 
early death in CF patients [16, 195]. 
In order to test new treatment options against these chronic infections predominantly 
caused by P. aeruginosa, suitable in vitro models mimicking this situation need to be 
developed. P. aeruginosas ability to build biofilms has been studied quite extensively 
on abiotic surfaces (e.g., glass or plastic), in static, or even flow cell conditions [112]. 
Additionally, growth conditions and ways of staining resulting biofilms of this pathogen 
have been published [100, 186]. However, studying the infection and biofilm 
development on a more relevant substrate (e.g., human cells), would help to better 
understand the airway infections as they occur in CF patients [112]. 
The first tissue-culture based model to study biofilm formation on human epithelial 
cells derived from a CF patient was reported by Anderson et al. [112]. They infected LCC 
cultivated CFBE41o- cells with P. aeruginosa PA14 with a multiplicity of infection (MOI, 
ratio of bacteria to originally seeded epithelial cells) of 30:1 and found that 4 to 6 h 
after the infection most of the epithelial cells had died presumably because of bacterial 
killing. This time window however did not allow for efficient biofilm formation. In an 
effort to find more suitable conditions, that would allow biofilm formation while 
keeping the epithelial cells alive, they discovered that the addition of arginine to the 
tissue culture medium preserved the integrity of the cell monolayer for up to 9 h, thus, 
allowing for more time for the biofilm formation. Furthermore, it could be shown that 
arginine also enhances P. aeruginosas ability to build a biofilm grown on an abiotic 
surface [187]. 
However, even though co-cultivation was possible, one major aspect, the cultivation at 
the air-liquid interface, as it would be found in vivo, was not addressed. The same 
group further improved the model and cultivated the epithelial cells on permeable 
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filters at ALI conditions. Nevertheless, Moreau et al. did not keep the ALI conditions 
after the infection with P. aeruginosa PAO1 (MOI 20:1), but rather continued with LCC 
growth of the co-culture [27, 111, 160]. Interestingly, they found that biofilms grown 
on biotic surface develop much faster and to greater extent than abiotic grown 
biofilms. To achieve biofilms equal to those found when cultivated on top of human 
cells after 6 h, P. aeruginosa needs to be grown on an abiotic surface (e.g., plastic) for 
at least 24 h. In addition, also the resistance to antibiotics increased dramatically when 
biofilms were grown on cells [160, 196]. 
These facts support the hypothesis that a co-culture model is most relevant to evaluate 
novel anti-infectives and treatment options. The aim was therefore to further improve 
the above-mentioned models by keeping the ALI conditions during the whole 
experiment and also increase the possible time of the co-culture before the cells 
succumb to the infection. This would not only mimic the actual in vivo situation better, 
but would also allow the evaluation of aerosolized anti-infective treatments for safety 
and efficacy on that model.  
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6.2 Material and Methods 
6.2.1 Direct infection approach 
Since first biofilm development can already be observed a couple hours after an 
infection [160] with P. aeruginosa, the direct infection with the pathogen was used to 
achieve a co-culture of human bronchial epithelial cells and P. aeruginosa biofilms. 
Thus, an overnight culture of PAO1 (see section 5.2.1) was prepared and diluted to an 
OD600~0.1. With reference to literature data and results from preliminary experiments a 
MOI of 20:1 was used to infect the human cells as soon as they built a tight monolayer 
and showed barrier properties (typically 7 after seeding for CFBE41o- and 12 days after 
seeding for Calu-3 cells, respectively). Since different amounts of the human cells were 
seeded in the beginning (see section 3.2.1) 15 µl for CFBE41o- and 30 µl for Calu-3 cells 
of the washed and diluted overnight culture had to be used to achieve a MOI of 20:1. 
To allow a better distribution of the bacteria on top of the cell monolayers these 
amounts of the overnight culture were diluted with M63 to achieve a total volume of 
100 µl per well. Cells were infected with this solution and incubated for 1  h. After that 
time unattached bacteria and excessive medium were carefully removed and the 
basolateral medium changed to medium that was additionally supplemented with 0.4% 
arginine since this promotes biofilm formation and helps the cells survive the infection 
[112, 187, 197]. 
6.2.1.1 Determination of colony forming units (CFU) 
The supernatants of each well were removed 24 h after the infection, transferred into 
Eppendorf® tubes and serially diluted (1:10) with PBS. A volume of 100 µl per samples 
was then plated on agar plates to determine the planktonic colony forming unit (CFU) 
fraction of the co-culture. Inoculated plates were incubated overnight at 37°C. 
Resulting colonies were counted the next day and the CFU calculated accordingly.  
6.2.2 Light microscopy images of epithelial cells and co-culture 
The co-culture was imaged 4, 8 and 24 h after the infection with P. aeruginosa PAO1 
with a light microscope (Axiovert 25; Zeiss, Jena, Germany) and an attached digital 
camera (Canon EOS 600D, Canon, Tokio, Japan). 
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6.2.3 Scanning electron microscopy 
For SEM images the supernatants from each well were removed carefully and the cells 
washed once with 100 µl apical and 1 ml PBS basolateral. Samples were then fixed with 
3% glutaraldehyd for 2 h at RT and subsequently washed with PBS. Afterwards the co-
culture was de-hydrated with a graded series of ethanol (each step for 10 min from 30-
100%). The filters were then cut from their Transwell® support and mounted on 
aluminium stubs, which were equipped with a carbon disc, and next sputtered with 
gold (Quorum Q150R ES, Quorum Technologies Ltd, Laughton, UK). SEM images were 
taken under vacuum conditions with an EVO HD 15 microscope (acceleration voltage 
5kV; Software SmartSEM, Zeiss, Jena, Germany). 
6.2.4 Confocal laser scanning microscopy 
For confocal images epithelial cells and P. aeruginosa PAO1 were pre-labelled with 
Vybrant® CFDA SE Cell Tracer Kit (Invitrogen) and CellTrace™ Far Red (Thermo Fisher 
Scientific), respectively, according to the manufacturer’s protocol before coming in 
contact with each other. Briefly, the medium from epithelial cells was removed and 
cells were incubated with 500 µl PBS with Vybrant® CFDA Cell Tracer (5 µM working 
solution). After 15 min at 37°C the staining was removed and 500 µl of medium added 
apically to inactivate excessive dye. For the bacteria the overnight culture was washed 
and diluted to OD600~0.1 as described under 5.2.2. The required amount of bacteria was 
pelleted and diluted in PBS containing CellTrace™ Far Red (10 µM working solution) for 
20 min at 37°C. After that time 5x the staining volume of medium was added to 
inactivate unnecessary dye and bacteria were incubated for another 5 min. The bacteria 
were then pelleted again and resuspended in M63 to be used for the infection. After 
the appropriate infection period, the co-culture was fixed with 800 µl of 3% PFA from 
the basolateral side for 30 min at RT. Subsequently, nuclei were stained with DAPI 
(200 ng/ml, Life Technologies, Darmstadt, Germany) for 30 min at RT. The co-culture 
was washed once with 300 µl of PBS and filters cut from Transwell® support and placed 
on a glass slide, mounted with 1 drop of DAKO and covered with a cover slip. Samples 
were then examined with Zeiss LSM 710 confocal laser scanning microscope (Zeiss, 
Jena, Germany). Images were taken with a 1024×1024 resolution using the 25x water 
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immersion objective (Fluotar VISIR 25x/0.95 water) and processed with ZEN 2012 SP1 
(black edition) software (Zeiss). 
6.2.5 Preformed biofilm approach 
For biofilm growth an overnight culture of PAO1 in exponential growth phase was 
washed and diluted to an OD600 0.1 (CFU/ml ∼ 5x107) and 15 µL of this dilution were 
used to inoculate minimal medium M63 (M63, supplemented with 0.4% arginine) to a 
final volume of 200 µl in 24-well plates. Cultures were then incubated under static 
conditions at 37°C for another 24 hours to allow biofilm formation. This was confirmed 
in preliminary experiments with crystal violet staining (see section 5.3.1). To evaluate 
the MOI for the infection with the preformed biofilm, the CFU of such a 24 h old biofilm 
was measured by plating serial dilutions of the biofilm on agar plates as described 
under 6.2.1.1. 
Tight monolayers of Calu-3 cells and CFBE41o- cells cultivated at ALI conditions were 
then infected with such preformed biofilms. Therefore, biofilms were scratched with a 
pipette tip from 24 well plates and one biofilm per well was transferred to the apical 
side of the epithelial cells. The so transferred biofilms were allowed to attach to the 
human cells for 1 h. Subsequently, unattached bacteria were removed from the apical 
side by carefully aspirating the supernatant with a pipette. Additionally, the basolateral 
medium was changed to cell culture medium that was additionally supplemented with 
0.4% arginine. The integrity of the epithelial cells was checked 4 and 24 h after the 
infection with a light microscope (ZEISS, Vert.A1). 
6.2.5.1 GFP labeled strain PAO1-GFP 
Another possibility to visualize the bacteria is the use of a fluorescent labelled strain 
like ATCC® 10145GFP™. This strain carries a plasmid on which the green fluorescent 
protein GFPmut3 is encoded. This protein exhibits a green fluorescence under UV light 
(Excitation: 501 nm; Emission: 511 nm) and offers the possibility to visualize the 
bacteria without further staining. The same plasmid also carries an ampicillin resistance 
gene. To avoid the loss of the plasmid, and therefore the green fluorescence during 
culturing, it is mandatory to maintain a concentration of 300 μg/mL ampicillin at all 
times in the culture medium. Through this measure the bacteria will keep the plasmid 
as selective advantage when replicating, and thus the possibility to visualize them with 
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UV light. The growth rate of PAO1-GFP is a little lower than that of the regular PAO1 
strain (data not shown). This is probably due to the fact that the PAO1-GFP bacteria 
face a higher selective pressure (i.e., culture medium with ampicillin), and also need 
time to double the plasmid containing the fluorescent protein when replicating. 
However, the growth rate does not necessarily influence the ability to form a biofilm 
[198]. In addition, biofilm formation is dependent on the nutrient conditions [183, 184]. 
Since these were kept the same for both PAO1 and PAO1-GFP, the produced biofilm 
after 24 h was considered equivalent in these studies. 
6.2.6 Confocal laser scanning microscopy 
The GFP labelled strain P. aeruginosa PAO1-GFP was used when confocal images had to 
be taken during the experiment. For cultivation and biofilm formation see 5.2.2. and 
5.2.2.1. The co-culture was stained apically with propidium iodide (PI) (40 µg/ml PI in 
PBS) for 15 min and washed once with PBS prior to the fixation with 800 µl 3% 
paraformaledhyd from the basolateral side at RT for 30 min. Afterwards cell nuclei and 
extracellualar DNA were stained with 300 µl DAPI (200 ng/ml, Life Technologies, 
Darmstadt, Germany) for 30 min from the apical side at RT. In view of the fact that PI 
can only enter a cell and intercalate with its nucleic DNA when the membrane is already 
damaged, this staining allows to differentiate between dead cells (red nuclei from PI) 
and living cells (blue nuclei from DAPI). After DAPI staining the co-culture was washed 
once with 300 µl PBS and the filters were cut from the Transwell® inserts. They were 
transferred on glass slides mounted with one drop of DAKO and covered with a 
coverslip. Samples were examined with a Leica TCS SP8 microscope with AOBS beam 
splitter and Leica HyD detector (Mannheim, Germany). Images were taken with a 
1024×1024 resolution using the 25x water immersion objective (Fluotar VISIR 25x/0.95 
water) and processed with LAS X software (Leica).  
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6.3 Results and Discussion 
6.3.1 A direct infection and live biofilm formation on the epithelial cells does not lead 
to a stable model 
Similar to Moreau-Marquis et al. [160] the ALI cultivated epithelial cells were infected 
with an overnight culture of P. aeruginosa PAO1 (MOI 1:20), but opposed from their 
protocol ALI conditions were kept during the whole experiment. Images of the co-
culture were taken after 4, 8 and 24 h with a light microscope or after fixation with a 
scanning electron or confocal scanning laser microscope. 
Calu-3 cells seem to tolerate the infection very well for the first 4 h, as depicted in 
Figure 6.1 A. The cells form a tight monolayer with clearly visible cell boundaries and no 
signs of cell death. However, 8 h after the infection (Figure 6.1 B) Calu-3 cells appear to 
have a slightly rounder shape and first dead cells are visible on the apical side. Although 
cells still form an intact monolayer, these are already signs that the cells are starting to 
die due to the infection. Even more evident is the situation 24 h after the infection 
(Figure 6.1 C). No epithelial cells can be detected anymore, indicating that the 
monolayer was disrupted and more or less all Calu-3 cells died due to the overgrowth 
with the pathogen. Given that the uninfected control cells (Figue 6.1 D) still form a 
confluent monolayer 24 h after the infection experiment was started, it’s evident that 
the cell death must indeed be caused by the infection with P. aeruginosa. 
If the amount of mucus present on the cells at the time of the infection has an 
influence was not investigated in this thesis. But considering the role mucus plays for 
the CFBE41o- cells (see chapter 4.3.3), it might indeed improve the survival of the cells 
after the infection. In Figure 3.6 B a homogenous mucus layer was found on the cells 
grown at ALI conditions. In addition to these findings also several other studies show a 
confluent mucus layer on top of the Calu-3 cells after 10-14 days at ALI conditions [139, 
144, 156, 199], while one group reported that mucus production might also depend on 
the used passage of the cells and a confluent mucus layer may take up to 21 days to be 
build up [145]. Although further experiments showed that the Calu-3 cells are more 
vulnerable to the P. aeruginosa infection and are therefore not the first choice as cell 
line for the in vitro model, the influence of the mucus amount present at the time of 
the infection might still be of interest and should be further investigated. Especially in 
view of the fact that mucus plays a major role in the CF pathogenesis and has influence 
Co-culture of human bronchial epithelial cells and P. aeruginosa PAO1 
 
- 85 - 
on how the pathogen can interact with the underlying epithelium [200], a longer 
cultivation time leading to a thicker mucus layer might prolong the survival of the 
infected Calu-3 cells. 
 
 
 
Figure 6.1 Morphology of Calu-3 cells infected with P. aeruginosa PAO1. Light microscopy 
images of the co-culture cultivated at ALI conditions were taken 4, 8 and 24 h after the 
infection with PAO1 (MOI 20:1). At the first two time points (A and B) an intact monolayer is 
still evident. No Calu-3 cells can be recognized in the image taken 24 h (C) after the infection. 
Picture D shows the uninfected control after 24 h. Scale bar: 200 µm major image and 100 µm 
enlargement top right corner. 
 
Similar results were obtained when the CFBE41o- cells supplemented with human 
mucus were infected with a MOI 20:1 of P. aeruginosa PAO1. 
Four hours after the infection (Figure 6.2 A) cells still form a confluent monolayer with 
no indication of cell stress. Yet, another 4 h later CFBE41o- cells start to show a rounder 
shape (Figure 6.2 B), a sign for starting necrosis or apoptosis. First dead cells (see 
enlargement in 6.2 B) can be seen on top of the still intact monolayer. Another 16 h 
later, 24 h after the infection, no epithelial cells (indicated by clear cell boundaries as in 
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images 6.2 A and B) can be identified anymore. Just a mixture of biofilm and planktonic 
bacteria all over the well is visible. Here again the uninfected control of the human cells 
(Figure 6.2 D) indicates that the infection is cause for the evident cell death. Similar 
results obtained by Anderson et al. [112] and Moreau-Marquis et al. [111] show that 
the CFBE cells were not able to withstand the infection with P. aeruginosa for more 
than 8 h due to the rapid bacterial overgrowth. In addition, their used co-culture model 
was not kept at ALI conditions after the infection with P. aeruginosa, which is 
mandatory for aerosol application. 
 
 
 
Figure 6.2 Morphology of CFBE41o- cells infected with P. aeruginosa PAO1. Light microscopy 
images of the co-culture cultivated at ALI conditions were taken 4, 8 and 24 h after the 
infection with PAO1 (MOI 20:1). At the first two time points (A and B) an intact monolayer is 
still evident. No clear cell boundaries of the CFBE41o- cells can be recognized in the image 
taken 24 h (C) after the infection. Picture D shows the uninfected control after 24 h. Scale bar: 
200 µm major image and 100 µM enlargement top right corner. 
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One possible option to enhance the survival of the model could be to incorporate 
repeated washing steps into the experimental protocol. This would allow to reduce the 
number of planktonic bacteria, which are the leading cause of acute toxicity and cell 
death of the human bronchial epithelial cells due to their rapid growth. Also, a major 
threat in acute P. aeruginosa infections, the activation of the type 3 secretion system 
could be kept under control by such a measure [111, 112, 201, 202]. 
To get better insight into the status of the in vitro model after 24 h, the remains of the 
co-culture were fixed and SEM images were taken. As shown in Figure 6.3, a layer of 
biofilm grown bacteria is covering the Transwell® insert. No sign of the former 
epithelial cell monolayer can be detected and in the enlargements (Figure 6.3 right 
side) even the pores of the Transwell® filter are visible, a clear sign that human cells 
underneath the bacteria are destroyed. Notably, the bacteria seem to be embedded in 
some kind of matrix. This self-produced matrix is typical for biofilms and is responsible 
for the adhesion of the biofilm to surfaces and forms the scaffold for their 3-D 
architecture. It consists of the so-called EPS (extracellular polymeric substances). These 
include polysaccharides, proteins, lipids and nucleic acids. The eDNA (extracellular 
deoxyribonucleic acid) is a major component of the EPS, especially in P. aeruginosa 
biofilms. Here it is responsible for stabilization of the biofilm and functions as 
intercellular connector [32, 203]. Some of the eDNA from lysed epithelial cells might be 
a part of the matrix seen in Figure 6.3. 
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Figure 6.3 Morphology of Calu-3 and CFBE41o- cells infected with P. aeruginosa PAO1. SEM 
images of the co-culture of Calu-3 (A) or CFBE41o- (B) and PAO1 cultivated at ALI conditions 
were taken 24 h after the infection (MOI 20:1). At this stage only a biofilm of PAO1 covering 
the whole well but no viable epithelial cells are visible. Pores of the Transwell® filter 
membrane can be seen in the enlargements in the darker gray areas. This holds true for both 
Calu-3 (Figure 6.3 A) and CFBE41o- cells (Figure 6.3 B) in co-culture with PAO1. Scale bar: 
50 µm left images and 5 µm enlargements on the right. 
 
Even though cells did not survive the infection beyond 24 h and first signs of a starting 
cell death can be detected as early as 8 h after the infection, a biofilm development on 
a still intact monolayer can be seen already after 4 h. 
The confocal images in Figure 6.4 show the CFBE41o- and Calu-3 cells in co-culture with 
P. aeruginosa PAO1 4 h and 8 h after the infection, respectively. At the earlier time 
point only small colonies of PAO1 (red color) can be seen on the intact monolayer of 
the CFBE41o- cells (Figure 6.4 A), as indicated by tight pattern of blue stained nuclei 
and green cytoplasma. Bacterial colonies increase during the course of the infection 
and 8 h after the infection approximately 25% of the Calu-3 cells are covered with 
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biofilm. Even though nuclei still form a tight pattern, their shape and also the blurry 
green color are signs for the starting cell death of the human lung epithelial cells.  
 
 
 
Figure 6.4 CLSM images of CFBE41o- or Calu-3 cells infected with P. aeruginosa PAO1. CLSM 
images of the co-culture of CFBE41o- (A) or Calu-3 (B) and PAO1 cultivated at ALI conditions 
were taken 4 h or 8 h after the infection (MOI 20:1), respectively. Human cells were stained 
with CFDA SE (green) and PAO1 with CellTrace™ Far Red (red). Nuclei were stained with DAPI.  
After 4 h small biofilm aggregations are visible on top of the CFBE41o- cells. Eight hours after 
the infection almost 25% of the Calu-3 cells are covered with attached bacteria. Scale bar: 
20 µm. 
 
Taken all the obtained results into account it is obvious, that a direct infection 
approach with biofilm development on the cells does not lead to a stable model where 
a rather mature biofilm co-exists with viable epithelial cells. To some extend a viable 
co-culture with some biofilm development could be achieved after 4 h. Furthermore, 
Moreau-Marquis et al. could show that biofilm formation on CFBE41o- cells is 1500-fold 
increased compared to abiotic biofilm growth after 6 h [160]. However, this does not 
reflect the situation in vivo with much older and more mature biofilms. Therefore, in 
order to achieve a stable model with both a mature biofilm and viable epithelial  cells 
another approach had to be taken.  
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6.3.2 Application of a preformed biofilm of P. aeruginosa to achieve a co-culture 
model ready for testing of novel drug delivery systems 
The direct infection with PAO1 and live biofilm development on the cells did not lead to 
a stable model suitable for further drug testing (see chapter 6.3.1). In order to get a 
more mature biofilm in co-culture with the human bronchial epithelial cells, the biofilm 
was preformed externally for 24 h and then transferred to the apical side of the cell 
monolayer. After the initial attachment phase of the transferred biofilm, planktonic 
bacteria were removed manual with a pipette and the co-culture was further kept at 
ALI conditions. This set up now allowed the application of aerosolized drugs for their 
safety and efficacy evaluation. 
The CLSM images in Figure 6.5 show the co-culture of Calu-3 (A) or CFBE41o- (B) with 
biofilms of P. aeruginosa PAO1-GFP on top one hour after the infection. Both cell lines 
depict a tight monolayer with just a few dead cells visible on top. Notably, the CFBE41o- 
co-culture (Figure 6.5 B) appears to have more dead cells on top then the Calu-3 co-
culture (Figure 6.5 A). However, this might be an artefact of the depicted section of the 
well (14% of the whole growth area), since in truth the Calu-3 cells are more 
susceptible to the infection. This will be discussed in detail in following chapter. 
The green labelled bacteria form small clusters on top of the human cells, but do not 
cover them completely. Bearing in mind that the biofilm is transferred manually with a 
pipette to the apical surface of the epithelial cells and consequently has to endure 
some physical forces, can partially explain the small biofilm fractions found in 
Figure 6.5. Nevertheless, biofilms have astonishing self-healing properties as shown by 
Lieleg et al. [204]. Despite the fact that bigger biofilm agglomerates might have been 
destroyed by means of pipetting the biofilm from the culturing well of the pre-formed 
biofilm (see section 6.2.5) to the apical epithelial cell surface, the remaining smaller 
biofilm fragments will recover their former viscoelastic behaviour and the ruptured 
interactions between biofilm polymers and the bacteria will be re-established within 
minutes [204]. On the other hand, these smaller biofilm fractions as seen in the CLSM 
images (Figure 6.5) might even mirror the in vivo situation better. Here, the biofilm can 
be found only in some sections of the lung tissue rather than covering the whole 
surface comprehensively [205]. 
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Figure 6.5 CLSM images of Calu-3 or CFBE41o- cells infected with P. aeruginosa PAO1 
biofilms. CLSM images of the co-culture of Calu-3 (A) or CFBE41o- (B) and PAO1 biofilms 
cultivated at ALI conditions were taken 1 h after the infection. Nuclei were stained with DAPI 
(blue) and dead human cells were counterstained with PI (red). The fluorescent labeled strain 
PAO1-GFP (green) was used. One hour after the infection with the preformed biofilm a tight 
monolayer of epithelial cells with few dead cells on top is visible. The bacteria in the biofilm 
can be found in small clusters on top of the human cells. Scale bar: 100 µm. 
 
Although the biofilm was cultivated for 24 h before being transferred to the epithelial 
cells and can therefore be considered as rather mature, it differs from biofilms grown 
on biotic surfaces. However, according to the literature [160, 196] at least 24 h of 
maturation on abiotic surfaces (e.g., plastic of culture dishes) are necessary to provide 
an equal mature biofilm as it would appear when grown for 6 h on a biotic surface (e.g., 
epithelial cells). 
Another option for further improvement of the model would be to use even older 
biofilms (e.g., 48 h or 72 h old). Furthermore, there is the possibility to pre-grow the 
biofilm on human epithelial cells prior to transferring it to the actual model. This will 
inevitably lead to the death of those host cells but will also offer a more physiological 
substrate and could enhance the maturation of the biofilm.  
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To further evaluate the role of mucus in the CFBE41o- co-culture model and to get 
images of the biofilm fragments with higher magnification, SEM pictures of the co-
culture were prepared 1 h after the infection (Figure 6.6). A tight monolayer of the 
epithelial cells with their typical small microvilli-like structures can be observed. A 
fragment of the previously applied mucus is indicated by the black arrow 
(Figure 6.5 left). Biofilm agglomerates (white arrows) of different sizes and also some 
single bacteria are visible on top of the human cells. The enlargement on the right 
shows that most of the bacteria are embedded in some kind of matrix or are connected 
by fibers. The presence of such biofilm fragments shows that with the transfer of the 
pre-grown biofilm a successful relocation of an already existing biofilm is possible. 
Seeing that this co-culture was fixed and imaged already 1 h after the infection, proofs 
that not only planktonic bacteria are transferred during the set-up, since the time into 
the infection would be rather to short two allow a biofilm formation of that extent.  
Similar to the CLSM image (Figure 6.5 B) the bacteria are not covering the whole cell 
surface but rather form agglomerates in certain areas. 
 
 
 
Figure 6.6 SEM images of CFBE41o- cells infected with P. aeruginosa PAO1 biofilms. Scanning 
electron microscopy images taken 1 h after the infection show an intact CFBE41o- monolayer in 
co-culture with PAO1 biofilms. On top of the monolayer some mucus fragments (black arrow), 
planktonic bacteria and biofilm agglomerates (white arrows) can be seen. The single bacteria 
can be considered as planktonic. The enlargement on the right shows microvilli like structures 
of the CFBE41o- cells and biofilm agglomerates. Scale bar: 100 µm left images and 5 µm 
enlargement on the right. 
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Further co-cultivation of the CFBE41o- cells with the preformed biofilm led to 
monolayer disruption and cell death as early as 4 h after the infection (data not shown). 
But considering that the bacterial load on the epithelial cells during the infection with 
the preformed biofilm is considerably higher as in the case of the direct infection (MOI 
1800:1 preformed biofilm approach versus 20:1 direct infection), the earlier death of 
the host cells in this method can be explained. 
Nevertheless, also in the case of the application of a preformed biofilm regular washing 
steps after certain time periods (e.g., 1 h) would additionally enhance the survival of 
the model by removing the planktonic bacteria as already discussed under 6.3.1 for  the 
direct infection approach. 
So even though several options for further improvement of the model seem feasible 
and are currently evaluated, the experimental set-up described here now allowed 
safety and efficacy testing of aerosolized antibiotic-loaded NPs against P. aeruginosa 
biofilms in vitro by maintaining air-liquid interface conditions during the entire course 
of the experiment.  
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6.4 Conclusion 
To obtain an in vitro model mimicking the chronically infected lung of CF patients, the 
presence of a biofilm on top of the epithelial cells seemed mandatory. To further use 
this model for safety and efficacy testing of aerosolized drug delivery systems, ALI 
conditions were maintained during the whole experimental procedure. On the basis of 
previously published studies a direct infection of the epithelial cells with P. aeruginosa 
PAO1 was evaluated. Although first biofilm development could be detected just after 
4 h and was even further increased 8 h after the infection, this approach did not lead to 
a stable model, since first signs of a starting cell death of the human cells were evident 
at the 8 h time point as well. Twenty-four hours after the infection only a biofilm of 
P. aeruginosa remained on the Transwell® filters. 
To achieve a model with viable epithelial cells and a more mature biofilm a different 
approach had to be taken. With the application of a 24 h preformed biofilm on top of 
monolayers of bronchial epithelial cells an experimental protocol could be established 
that allows the testing of aerosolized antibiotic NP formulations against P. aeruginosa. 
Even though the epithelial cells showed signs of a starting cell death already after 4 h, a 
longer co-cultivation was not necessary since the two major components of the in vitro 
model, a tight epithelial monolayer with mucus, and a mature P. aeruginosa biofilm, 
were already present. Therefore, the preformed biofilm approach offers an appropriate 
time window to test aerosolized formulations against P. aeruginosa. 
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7 Treatment of the co-culture with ciprofloxacin loaded PLGA 
nanoparticles 
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7.1 Introduction 
The chronic infection with P. aeruginosa already at a young age and the associated lung 
inflammation and tissue destruction are the major cause for morbidity and mortality in 
CF patients [57, 58]. To prevent early bacterial infections reaching a chronic state, an 
antibiotic eradication therapy (AET) is administered as soon as possible after diagnosis 
of P. aeruginosa infection. However, there is no recommended therapy regime for 
P. aeruginosa infections at the moment [24, 60]. In almost all of the published AET 
studies the use of inhalation therapy is a key element. It typically consists of inhaled 
colistin or tobramycin with or without the additional administration of an oral antibiotic 
like ciprofloxacin [60, 206-208]. Also, the use of intravenous antibiotics was evaluated 
in some AET protocols [209, 210]. Although dose, duration of therapy, number of cycles 
and combinations of drugs vary in those studies, no AET protocol has shown clear 
superiority [24, 61]. Besides, the reported success rates in eradicating P. aeruginosa 
from AET studies vary between 61-100%. So even though mean eradication rates of 
81.2% can be achieved with some form of AET, there are obviously patients for whom 
this therapy is unsuccessful [24]. 
Once a chronic P. aeruginosa infection is established, a complete eradication of the 
pathogen is nearly impossible [61]. In order to at least maintain the lung health of the 
affected CF patients, administration of chronic suppressive antibiotics and enhancers of 
the mucociliary clearance have proven useful. The therapy here consists of inhaled 
tobramycin, aztreonam lysine, colistin, ifacaftor, dornase alpha, mannitol, 
corticosteroids, and/or hypertonic saline often in combination with oral antibiotics, 
corticosteroids and ibuprofen [9, 211]. Although the local drug concentration can be 
increased when administering these drugs via inhalation [59], therapies fail to 
completely eradicate P. aeruginosa. This is associated with the pathogen’s ability to 
build antibiotic resistant biofilms. Such bacterial communities where the pathogens live 
in a self-produced matrix of exopolysaccharides, DNA and proteins are much more 
resistant to antibiotic treatment than their planktonic counterparts [28, 32]. One major 
problem in treating such bacterial infection is the biological barrier represented by the 
thick mucus/ biofilm mesh, which often leads to failing penetration, low diffusion rates 
of the antibiotic into the biofilm, and inactivation of the antibiotic agent by biofilm 
components. Furthermore, nutrient depletion in parts of the biofilm might result in 
Treatment of the co-culture with ciprofloxacin loaded nanoparticles 
 
- 97 - 
bacteria entering dormant state, in which they are less susceptible to antibiotics [28, 
34-36, 147]. 
A novel approach to improve the treatment of chronic P. aeruginosa infections with 
antibiotics is their delivery by NPs [36, 71]. In contrast to the bare molecule, these 
carrier systems should be able to interact with the CF mucus and bacterial biofilm and 
be able to release their antibiotic cargo in a controlled manner immediately at the site 
of action. To enable those NPs to penetrate the thick mucus and biofilm mesh typical 
for cystic fibrosis, they need to have a suitable particle size, usually <200 nm [212-214]. 
Also their surface charge (Zetapotential) is of importance, since mucoadhesion is most 
prominent in positively charged NPs [214-216]. Such mucoadhesive particles (MAPs) 
adhere to the top layers of the mucus and are therefore not able to reach deeper zones 
of the mucus/biofilm mesh, as desired for particles destined to treat chronic 
P. aeruginosa infections where the bacteria hide in a thick mucus/biofilm mesh. In 
addition, such MAPs might not spread homogeneously within the mucus/biofilm, which 
could lead to an unbalanced delivery of the inhaled particles and possibly a decreased 
drug efficacy [217]. 
However, through sophisticated engineering of the NPs surface, their ability to 
penetrate the mucus/biofilm mesh or interact with its components might be further 
improved [36, 171]. Especially PEGylation of the NPs surface has gained attention, since 
it can enhance the mobility of those particles in mucus by shielding their surface 
charge, minimize adhesive interaction between the particle and mucin fibres,  and 
making them more hydrophilic [213, 217-220]. Also for NPs stabilized with a block 
copolymer like Pluronic® (non-proprietary name poloxamer; (poly(ethylene glycol)-
poly(propylene oxide)-poly(ethylene glycol) PEG-PPO-PEG), an enhanced mobility in 
mucus was described [199, 212, 221]. But since these block copolymers contain high 
numbers of PEG chains, the similar behaviour compared to PEGylated NPs comes as no 
surprise. Of note, effectiveness of such PEG and Pluronic® coatings is closely related to 
the molecular weight (MW). Nanoparticles densely coated with a low MW PEG show 
good mucus penetration, whereas high MW PEG can lead to mucoadhesion [222]. 
Furthermore, also the MW of the PPO segment of Pluronic® is of importance. It was 
found that Pluronic® types with a PPO MW ≥3kDA were able to actively shield the NPs 
charge and therefore also decrease their mucoadhesion [221]. 
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Engineering NPs of a desired size and charge and additional favourable surface 
properties is not trivial. Traditional NP precipitation methods lack control over the 
growth process, resulting in varying NP parameters such as size and polydispersity 
index (PdI) [212]. However, considering that particle size and distribution are important 
quality characteristics not only for pulmonary NPs, a precise preparation technique was 
needed. 
With help of the MicroJet Reactor (MJR) technology (Figure 7.1) it is possible to 
produce NPs under controlled condition. This is a technology of two impinging jets 
(solvent and non-solvent), which collide in a gas-filled chamber at an angle of 180°. By 
controlling flow rates, temperature and the gas flow (nitrogen) from the top opening, 
the particle size can be adjusted. Produced NPs can be collected from the fourth 
opening on the bottom [223]. These particles are made of the biocompatible and 
biodegradable Poly(lactic-co-glycolic) acid (PLGA) [224, 225] stabilized and coated with 
Pluronic® F68 (synonym: poloxamer 188). The antibiotic cargo is the fluoroquinolone 
ciprofloxacin, which is commonly used for treatment of chronic P. aeruginosa infections 
in CF patients. The drug-loaded NPs were then tested for safety and efficacy on the 
human bronchial epithelial cells alone and on the preformed biofilm co-culture model. 
 
 
 
Figure 7.1 Schematic of Micro Jet Reactor (MJR). The MJR set up consist of two pumps for 
solvent and non-solvent. Their streams collide in the middle of a gas filled chamber controlled 
by N2 flow. Resulting NPs can be collected from the bottom opening. The whole system is 
immersed in a 32.5°C water bath in order to control the process temperature.   
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7.2 Material and methods 
7.2.1 Nanoparticle preparation and characterization 
NPs were prepared and characterized by Dr. Nazende Günday-Türeli from MJR 
Pharmjet. Briefly, they were produced with an optimized nanoprecipitation method 
[212, 226] for which the MJR (MicroJet Reactor) technology was used. For the NPs used 
in these studies the solvent system contained 2% ciprofloxacin-SDS complex (equivalent 
to 1% ciprofloxacin) dissolved in a 0.5% PLGA in DMSO solution, whereas the non-
solvent system consisted of a 0.25% Pluronic® F68 in water solution. Both solutions 
were delivered to the MJR in a 1:10 flow rate with Smartline S100 pumps (Knauer, 
Munich, Germany). The angle of the two impinging streams was 180°. Nitrogen can be 
used to control the mixing time in the chamber and therefore can control the particle 
size. However, this was not the case for the here produced particles. Therefore, the top 
opening was sealed. Both MJR and the solvent delivering capillaries were submerged in 
a water bath with the purpose of ensuring a system temperature of 32.5°C. 
Subsequently the resulting NPs were collected from the bottom opening and purified 
with Visking dialysis membrane with a molecular weight cut-off (MWCO) of 10 kDa 
(VWR, Darmstadt, Germany). 
7.2.2 Cytotoxicity studies 
In order to evaluate the cytotoxic potential of the NPs and their single components 
(e.g., sodium dodecyl sulfate (SDS), ciprofloxacin as free drug, SDS-ciprofloxacin 
complex, complex-loaded NPs and unloaded (blank) NPs) increasing concentrations 
(from 50 - 500 µM) of these were applied on human bronchial epithelial cells. For that 
reason, Calu-3 and CFBE41o- cells were seeded with a density of 125,000 cells/cm² and 
62,500 cells/cm², respectively. Three days after seeding the cells into tissue culture 
plates, they were incubated with the above mentioned loaded NPs or their single 
components dissolved in KRB supplemented with 10% FCS. As negative control 
(0% viability) cells were treated with 1% Triton-X 100 dissolved in KRB and as positive 
control (100% viability) cells where only incubated with assay medium (KRB+10% FCS). 
The supernatant (SN) of the 500 µM loaded NPs was obtained by centrifugation of 2 ml 
NPs suspension in a Centrisart® I (MWCO 300 kDa; Sigma Aldrich) at 2000 g for 15 min. 
SN was then applied as second positive control to evaluate potential toxic effects of 
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solubile factors resulting from the NP preparation. Cell viability was assed 4, 8 and 24 
hours after incubation with the test compounds with an ToxiLight™ bioassay kit 
according to the manufacturer’s protocol with one minor modification. Just 10 µl of the 
cell supernatants were used for analysis. Viability values were calculated by subtracting 
the resulting cytotoxicity values from 100%. 
7.2.3 Nebulization of nanosuspension and Panotile eardrops 
To achieve a more reasonable application of the nanosuspension on the ALI co-culture 
than as pure solution, nebulization with an Aerogen® Solo chamber attached to the 
Aeroneb® lab micropump control unit (Aerogen Ltd., Galway, Ireland) was used to 
distribute the suspension on the samples. This device works with a vibrating palladium 
mesh to create an aerosol. A volume of 200 µl of NP suspension (350 µM lyophilized 
complex-loaded PLGA NPs dissolved in KRB supplemented with 10% FCS) or blank KRB 
with 10% FCS (as negative control) was added to the Aerogen® Solo chamber and 
continuously nebulized into the corresponding wells 1 h or 4 h after the infection with 
the preformed bacterial biofilm. In order to guide the created aerosol directly into the 
well, a nebulisation chamber developed in-house was attached to the Aerogen® Solo 
chamber. 
As comparison Panotile® CIPRO eardrops (1 ml contains: 2.32 mg ciprofloxacin 
hydrochloride equal to 2 mg/ml ciprofloxacin; additional ingredients: glycerol, 
polysorbat 20, sodium acetate, acetic acid 99%, methyl cellulose, hydrochloric acid and 
sodium hydroxide and water for injection) were chosen and applied in the same 
manner as the NPs. 
7.2.3.1 Recovery rate of nebulized nanocarriers 
To estimate the amount that landed on the co-culture after nebulization, 200 µl of the 
nanosuspension (350 µM) was nebulized into empty wells of a 12 well plate. After 
settling of the aerosol cloud the content of each well was recovered by pipetting the 
resulting liquid into Eppendorf® tubes. Samples were diluted 1:100 with KRB and the 
concentration was measured with an UHPLC method (Dionex Ultimate® 3000 UHPLC 
with an Accucore™ column (RP 18, 150 mm x 2.1 mm, 2.6 µm, Thermo Fisher Scientific 
Co., Waltham, MA, USA)). A solvent mixture of 0.02 M Na2HPO4 (adjusted to a pH 
Treatment of the co-culture with ciprofloxacin loaded nanoparticles 
 
- 101 - 
of 2.7) and acetonitrile in a ratio of 77:23 was used. Temperature in the column oven 
was set to 25°C. Flow rate during quantification was 0.2 ml/min with a resulting 
retention time of ciprofloxacin at 4.2 min. 
7.2.4 Transepithelial electrical resistance (TEER) 
To measure the barrier properties of the epithelial cells at the end of the experiment 
(e.g., 24 h after the infection) the medium from both compartments was removed, 
replenished with HBSS (Gibco™) (500/1500 µl) and incubated for 30 min at 5% CO2 
atmosphere and 37°C. Afterwards TEER was measured. 
7.2.5 Viability of human cells during and after the infection 
7.2.5.1 Viability assay – MTT 
Subsequently after measuring the TEER values (see section 7.2.4), the ALI conditions 
were restored and an MTT assay was performed to assess the viability of the cells. The 
negative control (0% viability) was treated with 1% Triton X-100 (Sigma-Aldrich) in HBSS 
for 30 min at 37°C. After that time the co-culture was washed (300 µl HBSS apical and 
500 µl basolateral) and all wells incubated with 300 µl MTT solution (500 µg/ml) apical, 
and 500 µl HBSS basolateral for 4 h at 37°C and 5% CO2 atmosphere. Following that, 
250 µl of apical MTT solution was discarded and replenished with 200 µl DMSO (Sigma-
Aldrich) to solubilise the resulting formazan crystals. Thirty minutes later the 
absorption at 550 nm was measured with a plate reader (TECAN, infinite M200 pro, 
Männedorf, Switzerland). 
7.2.5.2 PI staining and confocal scanning microscopy 
The co-culture was stained apically with propidium iodide (PI) (40 µg/ml PI in PBS) for 
15 min and washed once with PBS prior to the fixation with 800 µl 3% paraformaledhyd 
from the basolateral side at RT for 30 min. Afterwards, cell nuclei and extracellular DNA 
were stained with 300 µl DAPI (200 ng/ml, Life Technologies, Darmstadt, Germany) for 
30 min from the apical side at RT. In view of the fact that PI can only enter a cell and 
intercalate with its nucleic DNA when the membrane is already damaged, this staining 
allows to differentiate between dead cells (red nuclei from PI) and living cells (blue 
nuclei from DAPI). After DAPI staining the co-culture was washed once with 300 µl PBS 
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and the filters were cut from the Transwell® inserts. They were transferred on glass 
slides mounted with one drop of DAKO and covered with a coverslip. Samples were 
examined with a Leica TCS SP8 microscope with AOBS beam splitter and Leica HyD 
detector (Mannheim, Germany). Images were taken with a 1024×1024 resolution using 
the 25x water immersion objective (Fluotar VISIR 25x/0.95 water) and processed with 
LAS X software (Leica). 
7.2.6 SEM 
For SEM images the preparation of the co-culture samples with NP treatment was 
performed 24 h after the infection. The supernatants from each well were removed 
carefully and the cells washed once with 100 µl apical and 1 ml PBS basolateral. Further 
sample preparation was conducted as described under 6.2.3. 
7.2.7 CFU determination of planktonic and biofilm bacteria 
7.2.7.1 Determination of planktonic CFU 
The supernatants of each well were removed 24 h after the infection, transferred into 
Eppendorf® tubes and serially diluted (1:10) with PBS. A sample volume of 100 µl was 
then plated on agar plates to determine the planktonic CFU fraction of the co-culture. 
Inoculated plates were incubated overnight at 37°C. Resulting colonies were counted 
the next day and the CFU calculated accordingly. 
7.2.7.2 Determination of biofilm CFU 
To also assess the biofilm CFU of the co-culture after treatment with NPs the medium 
from TEER measurement (see 6.2.4) was removed carefully. Subsequently, 500 µl of PBS 
with 0.1% Triton X-100 (Sigma Aldrich) were added apically. The Transwell® plate was 
placed in a bacterial shaker at 37°C and 150 rpm for 20 min. The co-culture lysates were 
then scraped from the wells, transferred into Eppendorf® tubes, vortexed thoroughly 
for at least 3 min, serially diluted and plated on agar plates. CFU was determined the 
next day as described under 7.2.7.1. 
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7.2.8 Statistical analysis 
Data are presented as mean ± standard error of the mean (SEM) from 3 independent 
experiments (n≥9) for safety evaluation of the NPs. Viability of the co-cultured cells 
after treatment was determined in 5 independent experiments (n≥5). For the efficacy 
testing of the NPs on the co-culture (CFU) ≥3 separate experiments with n≥8 were 
conducted. Statistical analysis was performed with the GraphPad Prism 5 software. The 
differences in viability were compared with a Two-way ANOVA and a Bonferroni post 
test; * p < 0.05, *p < 0.01 and *** p < 0.001 were considered significant.  
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7.3 Results and Discussion 
7.3.1 Ciprofloxacin-complex loaded PLGA nanoparticles are well tolerated by human 
cells 
The NPs used in these studies were prepared with an optimized nanoprecipitation 
method using the MicroJet Reactor (MJR). With this MJR technology nanoparticles can 
be produced under controlled conditions [226]. The resulting nanoparticles were of 
spherical shape and had a size of 190 ± 29 nm with a PDI of 0.089 [212]. They are 
composed of PLGA and Pluronic® F68, and were loaded with a complex of ciprofloxacin 
and SDS. 
The polyester PLGA is a biocompatible and biodegradable co-polymer of poly lactic acid 
(PLA) and poly glycolic acid (PGA). These two monomers result again when PLGA 
undergoes hydrolysis. It was found that a higher content of glycolic acid in the oligomer 
resulted in a faster degradation rate. Glycolic acid and lactic acid can be easily 
metabolized via the Krebs cycle. Thus, PLGA is associated with minimal systemic 
toxicity. It’s approved by the Food and Drug Administration (FDA) and the European 
Medicine Agency (EMA), although not for pulmonary applications yet [224, 225]. 
Block copolymers like Pluronic®, also known as poloxamers, are so called generally 
recognized as safe (GRAS) materials and are accepted pharmaceutical excipients in the 
US and British Pharmacopoeia. These copolymers consist of blocks of ethylene 
oxide (EO) and propylene oxide (PO) in an EOx-POy-EOx structure, giving them an 
amphiphilic character. They are widely used components of drug delivery systems 
because of their multiple effects [221, 227, 228]. The orange book, FDAs list of 
approved drug products, lists 57 drug products using poloxamers as excipients in 2018. 
The Pluronic® F68 (poloxamer 188) is used in almost half of them (28 approved drug 
products with this poloxamer) [229]. 
Due to their ability to incorporate into biological membranes and afterwards 
translocate into the cells, they can affect various cellular functions. For instance, it was 
shown that Pluronic block copolymers decrease the ATP synthesis, inhibit drug efflux 
transporters like MRP and Pgp, alter the mitochondrial respiration and enhance the 
apoptotic signal transduction. Furthermore, they can modify the cells gene expression 
[230]. These properties make them extremely valuable for drug delivery systems 
intended for cancer treatment or gene therapy. However, also enhanced bioavailability 
Treatment of the co-culture with ciprofloxacin loaded nanoparticles 
 
- 105 - 
and activity of antibacterial drugs against many microorganisms was reported for 
Pluronic® block copolymers [230]. Even though these polymers (e.g., Pluronic® F68) 
possess no antimicrobial properties of their own, they can markedly increase the 
activity of antibacterial drugs such as hexetidine when used in concentrations well 
below their critical micelle concentration [231]. 
In the NPs produced for these studies Pluronic® has a stabilizing function. In addition, 
the PEG chains incorporated in the NP shell through the use of Pluronic® might help to 
facilitate mucus and biofilm penetration of the NPs by increasing their mobility in these 
barriers and minimizing interactions with its components [226]. If the stabilizer also 
increases the activity of the here used drug ciprofloxacin will therefore be of interest in 
this work. 
Even though it could be shown that Pluronic® F68 itself does not induce cell mortality, 
an increase in cytotoxicity was observed in A549 cells, but not in Calu-3 cells when 
PLGA NPs stabilized with Pluronic® F68 where applied. This effect might be due to the 
high amount of NPs internalized into the cells, which is related to the stabilizer 
Pluronic® F68, since PLGA NPs formulated with different stabilizers (e.g., polyvinyl 
alcohol or chitosan) were internalized less frequently into the cells [199, 232]. 
As model drug the broad-spectrum fluoroquinolone, ciprofloxacin was chosen. It is 
already commercially available especially for treatment of Gram-negative bacterial 
infections (e.g., P. aeruginosa) but it also shows efficacy against Gram-positive 
pathogens (e.g., Staphylococcus aureus) [226]. However, the only commercially 
available ciprofloxacin formulations for the treatment of pulmonary infections are oral 
or intravenous drug forms. Pulmonary drug delivery on the other hand would lead to 
much higher local drug concentration in the airways, while at the same time decreasing 
the systemic exposure and therefore possible side effects [59]. Even though many 
studies with ciprofloxacin loaded nanocarriers (e.g., liposomes, nanoparticles or 
nanoplexes) for pulmonary application have been conducted and show promising 
results [212, 233-243], no inhalable ciprofloxacin formulation is on the market yet. 
Of note, only a dry powder for inhalation (DPI) loaded with ciprofloxacin from Bayer 
(BAYQ3939) and a formulation containing both ciprofloxacin loaded liposomes and free 
ciprofloxacin from Aradigm (ARD-3150 LinhaliqTM) completed phase III of clinical 
studies [244]. Nevertheless, even though results from the ciprofloxacin DPI studies 
(RESPIRE trials conducted by Bayer [243]) were promising, data showed an increase in 
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ciprofloxacin-resistant P. aeruginosa in patients that received the ciprofloxacin DPI 
compared to those treated with placebo. Also due to other study discrepancies the 
FDAs advisory panel voted against the approval of the drug [245], which will most likely 
result in the rejection of the new drug application (NDA). Bayer stopped further 
development on the DPI for the time being according to their annual report 2017 [246]. 
Also LinhaliqTM, formally known as Pulmaquin® (tested in two phase III trials ORBIT-3 
and ORBIT-4 by Aradigm) showed promising results [247] but did not get an approval 
from the FDA when filing for NDA due to mixed data from the two phase III clinical 
studies. Aradigm needs to perform a new phase III study before resubmission of NDA 
[248, 249]. Furthermore, both products were developed and tested for non-CF 
bronchiectasis and therefore only off-label-use would offer new treatment options for 
CF patient. Another liposomal ciprofloxacin formulation from Aradigm (ARD-3100 
Lipoquin) intended for CF treatment is currently in phase II of clinical studies showing 
promising results [250]. 
Nevertheless, taken together this shows the importance of further research on 
ciprofloxacin-loaded nanocarriers. 
Ciprofloxacin suffers from a low solubility and therefore low bioavailability. The drug is 
poorly soluble in organic solvents and a pH-adjusted aqueous solvent would lead to a 
faster degradation of the PLGA nanocarrier [251, 252]. Therefore, a drug loading of 
more than 5% with conventional particle preparation methods cannot be achieved 
[251]. In order to improve drug loading into the PLGA NPs the counter-ion method was 
utilized. To proof that with this method a higher drug loading is possible, a complex 
between ciprofloxacin and the counter-ion sodium dodecyl sulfate (SDS) was formed. 
The complex formation enhanced the solubility in organic media by 80-fold. In addition, 
also the antibacterial activity of ciprofloxacin increased in a synergistic way. This is 
probably due to a steric protection of ciprofloxacins functional group by SDS. Moreover, 
the drug loading efficiency was improved by complex formation and a drug loading of 
14% ciprofloxacin could be achieved. These findings exceed current results for NP 
loading with this antibiotic considerably [251]. 
In order to exclude any cytotoxicity triggered by the drug-loaded NPs or their individual 
components, they were applied on the Calu-3 and CFBE41o- cells in increasing 
concentrations. This also allowed determining the optimal dose for the following 
treatment of the co-culture. 
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Using the ToxiLight™ bioassay kit the viability of Calu-3 and CFBE41o- cells was 
determined. Both ciprofloxacin complex-loaded and drug free NPs, as well as their 
single components (i.e., ciprofloxacin, SDS, ciprofloxacin-SDS complex) were applied in 
increasing concentrations (50-500 µm) to the cells. As additional control also the 
supernatant of the complex-loaded NPs was evaluated for any cytotoxic potential. 
Viability of the cells was measured after 4, 8 and 24 h. Results of the lowest and the 
two highest applied concentrations of all tested compounds are shown in Figure 7.2. 
Ciprofloxacin (Cipro, Figure 7.2 A) exhibits no cytotoxic potential neither in Calu-3 or 
CFBE41o- cells. Due to the mentioned solubility issues only the concentrations 50 and 
100 µm were tested. 
SDS (Figure 7.2 B) decreased the cell viability in the highest applied concentration 
(500 µM) already significantly after 8 h. This was the case for both cell lines. However, 
this was no surprise, since SDS is a surfactant interfering with the cell membrane. 
Besides, one has to considering that the formed complex was used as proof-of-concept. 
In future also other, less toxic, excipients can be used as counter-ions. Thus, the here 
measured SDS toxicity should not be overrated. Besides, the second highest 
concentration (350 µm) did not show any cytotoxic potential after 24 h. 
As alternative counter-ion 1,2-Dipalmitoyl-sn-glycero-3-phosphatidic acid, sodium salt 
(DPPA) can be utilized. DPPA is biodegradable and easily synthesized precursor of 
natural lung surfactant [251], and thus a suitable substitute to SDS. 
The free Cipro-SDS complex (Figure 7.2 C) was well tolerated by the CFBE41o- cells even 
in the highest concentration. However, the Calu-3 cells showed a significant reduction 
of cell viability to 85 ± 4% after 24 h incubation with 500 µM complex solution. 
Drug-free NPs (Figure 7.2 D) were well tolerated by the bronchial cells. Nonetheless, a 
significant viability reduction was seen after 24 h in the CFBE41o- cells. But since this 
reduction is from 104 ± 1% and 103 ± 1% after 4 h and 8 h, respectively, to 99 ± 1% this 
result can probably be neglected. 
Similar results were obtained for the SN of the drug-loaded NPs (Figure 7.2 E). 
CFBE41o- cells showed significantly lower viability at the 24 h time point. The values 
decreased from ~110% to 106 ± 2%. However, considering that the viability is still 
around 100% this small drop can most likely be disregarded as well. 
The drug-loaded NPs in their highest concentration (Figure 7.2 F) decreased the viability 
from ~100% at 4 h and 8 h to 76 ± 9% and 81 ± 8% after 24 h incubation in the Calu-3 
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and CFBE41o- cells, respectively. Since the drug-free NPs did not show cytotoxic 
potential, it was concluded that the observed toxicity of the drug-loaded NPs was 
directly linked to the Cipro-SDS complex. This drop in viability was highly significant and 
even though more than 75% of the cells are alive after 24 h the second highest 
concentration (350 µM) was chosen for further experiments. 
It can be concluded that the NPs show a dose dependent toxicity, but are otherwise 
well tolerated by the epithelial cells. At the same time, they show no toxic effects in the 
second highest tested concentration (350 µM). 
Thus, proofing the safety of the drug-loaded NPs, the aim was now to show the efficacy 
of the DDS on the established in vitro co-culture model.  
Treatment of the co-culture with ciprofloxacin loaded nanoparticles 
 
- 109 - 
 
 
Figure 7.2 Viability of Calu-3 and CFBE41o- cells after NP application. Cell lines were treated 
with Cipro-SDS loaded NPs (F) or their single components i.e., Ciprofloxacin (Cipro, A), SDS (B), 
complex of Cipro-SDS (C), drug-free NPs (D) as well as the supernatant (SN) of the loaded NPs 
(E). Cytotoxictity of compounds was assessed with the ToxiLight™ bioassay kit. Resulting values 
were subtracted from 100% to obtain cell viability. Data shown are mean ± SEM (n≥9) from 
three independent experiments. *** p < 0.001; ** p <0.01. 
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7.3.2 Early treatment with drug-loaded NPs makes epithelial cells survive bacterial 
infection 
After the safety of the NPs was assured, they were evaluate for their potential to 
eradicate biofilm-grown P. aeruginosa on top of human bronchial cells and 
simultaneously preserve the integrity of the epithelial cell monolayer. For that purpose 
drug-loaded NPs or KRB buffer as control were deposited as an aerosol onto the co-
culture at the ALI at different time points. As read-outs SEM imaging, viability 
measurements, TEER measurement as well as CLSM images were used. 
When the antibiotic-loaded NPs were applied to the co-culture 1 h after the infection 
CFBE41o- cells still formed a tight monolayer when fixed and imaged 24 h later with 
SEM (Figure 7.3 B). Mucus and biofilm fragments can be seen on top of the cells, as well 
as a couple of single bacteria. The Calu-3 cells however, already show holes in the 
monolayer at the same time point (Figure 7.3 A). Lots of round cell debris can be seen 
in the top right part of the image. The enlargement shows that remaining cells still 
show the typical microvilli-like structures on their cell surface. Also biofilm parts with 
embedded bacteria remain on top of the Calu-3 cells 24 h after the infection and 23 h 
after the treatment with NPs. 
The situation looks much different when the aerosolized NPs are administered 4 h after 
the infection with P. aeruginosa biofilms. Calu-3 cells show an almost completely 
destructed monolayer (Figure 7.4 A). Piles of dead bronchial cells (spherical shaped 
debris) dominate the picture. The Transwell® filter with its pores can be seen in the 
enlargement, which is further evidence that the monolayer is heavily damaged. Single 
and biofilm-grown bacteria are higher in number compared to picture of the 1 h 
treatment time point (Figure 7.3 A). A similar situation was found for the CFBE41o- cells 
(Figure 7.4 B). Even though bigger coherent bronchial cell aggregates remain (left side 
of the image) a destruction of the cell monolayer is evident here as well. On the right 
side the underlying Transwell® filter is visible. A mixture of spherical cell debris, mucus 
and biofilm with embedded bacteria can clearly be detected in the enlargement. Also 
the total number of remaining bacteria (planktonic and biofilm) is higher than for the 
earlier treatment time point (Figure 7.3 B). 
These images already plainly indicate that in order to efficiently treat the cells and keep 
up their monolayer integrity, an early treatment is indispensable. 
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Figure 7.3 SEM images of Calu-3 or CFBE41o- cells infected with P. aeruginosa PAO1 biofilms 
and treated with drug-loaded NPs 1 h after infection. Cells were treated 1 h after the infection 
with the NPs. Co-culture was fixed 24 h after the infection. Calu-3 cells (A) already show holes 
in the monolayer, whereas CFBE41o- cells (B) still form a tight layer. Typical microvilli-like 
structures of Calu-3 cells are visible in the enlargement. Mucus and biofilm fragments with 
embedded bacteria are evident in top of both co-cultures. Scale bar: 50 µm left images and 
5 µm enlargements on the right. 
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Figure 7.4 SEM images of Calu-3 or CFBE41o- cells infected with P. aeruginosa PAO1 biofilms 
and treated with drug-loaded NPs 4 h after infection. Cells were treated 4 h after the infection 
with the NPs. Co-culture was fixed 24 h after the infection. Calu-3 cells (A) show a completely 
destructed monolayer with huge holes. Spherical cell remains dominate the picture. The 
CFBE41o- cells (B) show a remaining monolayer with bigger holes in some parts. Dead cells can 
be seen as well. Mucus and biofilm fragments with embedded bacteria are evident on top of 
both co-cultures. Planktonic bacteria are numerous in both images. The Transwell® membrane 
is visible in both cases. Scale bar: 50 µm left images and 5 µm enlargements on the right.  
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In order to also determine the actual viability of the human bronchial epithelial cells 
after the different treatment time points, viability assays (MTT) were conducted 24 h 
after the infection (Figure 7.5). The previously used viability assay (ToxiLight™ bioassay 
kit) requires cell culture supernatant. Since cells were cultivated at ALI only small 
amounts of supernatant were expected on the apical side of the co-culture. These 
amounts of supernatant, resulting from nebulization of the NPs, and cell culture 
medium transfer from the basolateral compartment to the apical compartment through 
holes in the cell monolayer, might however not be enough to utilize the ToxiLight™ 
bioassay kit. Thus, a different assay, not requiring supernatant for the measurement, 
was needed. Hence, the MTT assay with a more suitable assay protocol (see 7.2.5.1) 
was used in order to determine the cells viability (i.e., mitochondrial activity) after 
different treatment time points. 
Results confirm the decrease in viability already indicated by SEM images (Figure  7.3 
and 7.4). When Calu-3 cells (Figure 7.5 A) received treatment 1 h after the infection 
their viability after was still at 80 ± 22% 24 h after the infection. When the treatment 
was delayed for another 3 h only 50 ± 11% of the cells remained viable at the end of the 
experiment. 
With the purpose of examining the effect of mucus on the CFBE41o- cells when infected 
with P. aeruginosa biofilms, viability assays were conducted on cells that received 
mucus prior to the infection (striped bars Figure 7.5 B) and cells that did not (blank 
bars). Even with an early treatment (t = 1 h) viability of cells without mucus supplement 
had already decreased to 65 ± 9%. When antibiotic treatment was administered 4 h 
after the infection, viability had decreased even further to 51 ± 11%. When the 
experiment was conducted with cells that had received mucus, the viability of the cells 
treated 1 h or 4 h after the infection had improved to 94 ± 15% and 80 ± 6%, 
respectively. These data point out that mucus does not only enhance epithelial barrier 
properties (Figure 4.4), but also has a protecting role for the CFBE41o- cells against the 
bacterial infection. 
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Figure 7.5 Viability of Calu-3 and CFBE41o- cells after infection and treatment with NPs. 
Viability of Calu-3 (A) and CFBE41o- cells (B) was measured with an MTT assay. For the Calu-3 
cells a decline of cell viability was visible. An early treatment (1 h after infection) with the drug-
loaded NPs maintained 80% viability whereas a later treatment (after 4 h) resulted in only 50% 
viable cells 24 h after the infection. For the CFBE41o- cells an early treatment (after 1 h) with 
antibiotic NPs helps them to survive the infection. Cells covered by mucus (striped bars) 
conserved their viability even when NPs was performed at a later time point (after 4 h). 
Experiments were performed 5 times and results are presented as mean ± SEM. 
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CLSM images gave additional insight into the status of the co-culture after NP 
treatment at different time points (Figure 7.6). When treatment was administered 1 h 
after the infection Calu-3 cells already show signs of starting cell death (red nuclei, 
Figure 7.6 A) and holes in the cell monolayer. In contrast, CFBE41o- cells still form a 
complete monolayer and no PI stained (dead) nuclei were visible (Figure 7.6 B). A later 
treatment (t =4 h) led to an increase of red stained nuclei (Figure 7.6 D) and even some 
gaps in the cell monolayer. However, the Calu-3 cells (Figure 7.6 C) are in even less 
good conditions. Just patches of connected epithelial cells are visible and these cells 
also show signs of necrosis or apoptosis (red). The tight monolayer from the beginning 
of the experiment is gone. Of note, no living bacteria (green) could be detected in 
Figure 7.6 A-D. But considering the fact, that after 24 h just a small amount of bacteria 
(∼50 CFU/ml, see chapter 7.3.4, Figure 7.8 C and D) remains in the complete sample 
and the images just show roughly 14% of it, can explain the lack of the green signal in 
those images. Total cell monolayer destruction was the case when no antibiotic 
treatment (just KRB) was applied (Figure 7.6 E, F). No cell nuclei were visible anymore. 
Given that DAPI and PI both bind to DNA, which is abundant in biofilms, CLSM imaging 
of the same was feasible and revealed the typical 3-D like structures [181, 196]. The 
green labelled bacteria seem to dominate the picture of the Calu-3 co-culture while the 
biofilm of the CFBE41o- cells is composed of equal parts bacteria and DNA visible by the 
white colour (overlay of red, blue and green signal) of the mushroom like structure. It 
was reported by Moreau-Marquis et al. that biofilm formation is promoted when 
P. aeruginosa is grown on CF-derived cells. In addition, they could also show that the 
∆F508-CFTR mutation enhanced biofilm formation not just in CFBE41o- cells but also in 
a set of kidney cells with the same mutation [160]. Considering that the Calu-3 cells do 
not exhibit this mutation could be a possible explanation for the difference in the 
biofilm after 24 h (Figure 7.6 E, F). Whether the composition of both biofilms is indeed 
different or this is just an imaging artefact remains to be investigated. 
Taken together these CLSM data corroborate the previously presented results regarding 
cellular viability and monolayer integrity. As already indicated by the SEM images and 
the MTT assay, the CFBE41o- cells seem to cope much better with the infection 
provided they were supplemented with mucus. The question remains, if longer 
cultivation of the Calu-3 cells at ALI conditions prior to the infection and a resulting 
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higher amount of mucus on the cells would also increase their robustness. Nonetheless, 
an early treatment (t = 1 h) is to be favored in order to preserve cell viability and 
monolayer integrity. 
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Figure 7.6 Representative confocal images of co-cultures after treatment or without 
treatment. The co-cultures were fixed 24 h after the infection. When drug-loaded NPs were 
applied after 1 h (A, B) cells were still forming a confluent monolayer. Treatment after 4 h (C, 
D) resulted in increased cell death (red nuclei). CFBE41o- cells visibly cope better with the 
infection. Calu-3 cells show signs of cell death already at t = 1 h and loose cell aggregates when 
treatment is given at t = 4 h. No treatment (E, F) led to complete destruction of the cell 
monolayer for both cell lines and P. aeruginosa was able to build 3-D biofilm structures. DAPI 
(blue) was used to stain the nuclei of all cells  and propidium iodide (red) to label dead cell 
nuclei; P. aeruginosa strain PAO1 carries a plasmid with GFP (green). Scale bar: 100 µm.  
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7.3.3 Barrier properties of CFBE41o- cells can be maintained when treatment is 
administered 1 h after infection with P. aeruginosa biofilm, whereas Calu-3 loose 
barrier function even with an early treatment 
In view of the fact that mucus helped the CFBE41o- cells to survive the bacterial 
infection, when treatment was administered early enough, the role of mucus in 
maintaining epithelial barrier properties after the infection was a matter of particular 
interest. Thus, TEER measurements were performed 24 h after the infection and 
treatment with NPs (Figure 7.7). 
Calu-3 cells (Figure 7.7 A) lost their barrier properties (TEER = 28 ± 5 Ω*cm²) even when 
the NPs were deposited on the co-culture at t =1 h. Later treatment decreased this 
value even further to 13 ± 2 Ω*cm². Although both values are well below the 
300 Ω*cm² mark for barrier properties, this difference was significant. Cells that were 
not infected kept their epithelial barrier function and showed TEER values of 
351 ± 47 Ω*cm². Considering that the Calu-3 cells already showed holes in the 
monolayer even when NP treatment was given early (see Figure 7.3 A and 7.6 A) these 
results were not surprising. This emphasizes the fact that the Calu-3 cells are probably 
not the optimal cell line for the co-culture model under the given conditions. 
However, the situation looks much different for the CFBE41o- cells (Figure 7.7 B). The 
cells receiving human mucus prior to the infection exhibited almost twice as high TEER 
values as the cells without human mucus (361 ± 52 Ω*cm² versus 601 ± 75 Ω*cm²). This 
was at least true when antibiotic treatment was performed 1 h after the infection. 
When drug-loaded NPs were applied 4 h after the infection, CFBE41o- were not able to 
preserve their barrier properties even in presence of mucus (without mucus: 
49 ± 5 Ω*cm² versus 115 ± 29 Ω*cm² with mucus). 
Untreated co-cultures that just received nebulized KRB scarcely showed any remaining 
barrier function (data not shown; 12 ± 2 Ω*cm² and 10 ± 2 Ω*cm² for Calu-3 and 
CFBE41o-, respectively). However, this is in agreement with previous shown results of 
the completely destructed bronchial epithelium (Figure 6.3 and 7.6 E and F). In 
contrast, uninfected cells that also received NPs as a control (chequered bars in 
Figure 7.7) exhibited high TEER values after 24 h (351 ± 47 Ω*cm² for the Calu-3 cells 
and 2080 ± 273 Ω*cm² for CFBE41o- cells). This indicates that the nebulization process 
itself had no negative effect on the barrier properties of the cells. 
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Figure 7.7 TEER of Calu-3 and CFBE41o- cells after infection. For the Calu-3 cells (A) even with 
an early NP treatment (t=1 h) barrier properties were lost. CFBE41o- (B) barrier function could 
be maintained with an early treatment (t =1 h). Later treatment after 4 h resulted in loss of 
barrier properties as well. Values are presented as mean ± SEM.  
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7.3.4 CFU of P. aeruginosa can be reduced by 6-fold with an early treatment of 
infected co-culture 
After the safety and the effect of the NPs on the co-culture were assessed, also their 
efficacy in combating the biofilm-grown P. aeruginosa was investigated. In order to 
compare them to a commercially available product, Panotile® CIPRO was chosen as 
compromise. As mentioned previously no pulmonary applicable dosage form containing 
ciprofloxacin is on the market yet, not to mention one where the drug is encapsulated 
in NPs [212]. In addition, the product was aimed to be nebulized. Ciprofloxacin suffers 
from a low solubility [251]. Thus, the preparation of a ciprofloxacin solution with 
analogous drug content as the NPs solution was not feasible. One available product 
with ciprofloxacin already in solution is eardrops. Lacking a better option, the Panotile® 
CIPRO eardrops were chosen to compare the efficacy of the drug-loaded NPs with a 
market approved commercial product. After dilution with KRB (supplemented with 10% 
FCS) to the appropriate concentration (350 µM ciprofloxacin), they were deposited 
onto the co-culture in the same manner as the NPs. Nebulized KRB buffer served as 
negative control.  
The actual applied dose was assessed by measuring the recovery rate of the nebulized 
NPs suspension (350 µM) in a preliminary experiment. The recovered suspension had a 
concentration of 234 ±30 µM, which corresponds to a recovery rate of ∼70%. 
Furthermore, the nebulization process itself had no significant effect on the size of the 
nanocarriers. Due to the proteins found in the FCS from the dilution buffer (KRB with 
10% FCS) the formation of a corona could be observed [253]. The particles size 
increased from originally 190 ± 29 nm [212] to 374 ± 4 nm. The nebulization slightly 
reduced the size again to 320 ± 2 nm, the difference not being significant. 
The same treatment time points (1 h and 4 h after infection) where chosen to deposit 
aerosols of NPs, Panotile or KRB onto the co-culture. CFU/ml of planktonic and biofilm 
fraction of P. aeruginosa was determined 24 h after the infection by plating 
supernatant and lysates from each well on agar plates. 
Almost all supernatants from co-cultures that were treated with NPs 1 h after infection 
showed no bacterial growth (Figure 7.8 A and B). The small amount of remaining 
bacteria (3 CFU/ml) in the Calu-3 co-culture treated with NPs can probably be 
neglected. In addition, when treated after 4 h no viable bacteria remained in the 
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supernatant of the Calu-3 co-culture (Figure 7.8 A). In the CFBE41o- co-culture surviving 
planktonic bacteria were detected at 40 CFU/ml and 5 CFU/ml for NPs and Panotile®, 
respectively. But compared to the control wells (i.e., with KRB) where a bacterial 
growth of 1.1*109 CFU/ml (Calu-3) and 7.7*108 CFU/ml (CFBE41o-) was measured, 
these numbers show a log 8 reduction of CFU/ml counts. Accordingly, these data 
suggest that complete eradication of planktonic P. aeruginosa is possible, provided that 
antibiotic treatment is given early enough (1 h post infection). 
In order to also determine the efficacy of the drug-loaded NPs and Panotile® against 
the biofilm fraction, contents of each well were lysed with 0.1% Triton X-100 and plated 
on agar plates (Figure 7.8 C and D). In contrast to the planktonic bacteria a complete 
eradication of biofilm-grown bacteria was not possible even when the antibiotics (NPs 
or Panotile®) were administered already 1 h after infection. This is in agreement with a 
study by Moreau-Marquis et al., who observed that ciprofloxacin alone or even in 
combination with other antibiotics was not able to eliminate P. aeruginosa biofilms 
grown on airway cells. They report an increased resistance to clinically used antibiotics 
already 1.5 h after the initial infection [160]. Nonetheless, a significant reduction by 
log 6 of CFU/ml counts compared to the non-treated control (KRB only; 7.7*107 CFU/ml 
and 4.6*107 CFU/ml for Calu-3 and CFBE41o-, respectively) was observed in our study, 
the difference between t =1 h and t = 4 h being insignificant. However, results showed 
that NPs have a slightly better efficacy against biofilm-grown bacteria as the Panotile® 
CIPRO eardrops (24 CFU/ml compared to 264 CFU/ml in Calu-3 co-cultures, t = 4 h; 
29 CFU/ml versus 95 CFU/ml, t = 1 h and 52 CFU/ml versus. 183 CFU/ml, t = 4 h in 
CFBE41o- co-cultures; exception is 1 h treatment time point in Calu-3). Even though 
these results did not reach significance, they back up the hypothesis, that NPs can 
interact with mucus and biofilm components, achieve a depot effect and release the 
drug in a controlled manner. This assumption could be confirmed in the future by 
integrating additional washing steps in the experimental protocol. Only the NPs, which 
are able to attach to their deposition site, could release their antibiotic cargo and 
combat P. aeruginosa, whereas the Panotile® CIPRO solution would be washed away. 
Moreover, NPs could be able to protect the drug from inactivation by biofilm 
components [36]. This cannot be realized with Panotile® eardrops, where the drug is 
already dissolved, thus, making an interaction with mucus and biofilm improbable. To 
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verify this hypothesis additional studies with even older biofilms (48 h or older) and 
repeated dose applications will give further insight in the potential of such DDSs. 
Additionally, in future the drug-loaded NPs can also be formulated into microparticles, 
and thus meeting the necessities in size, shape and aerodynamic properties (see 
introduction 1.3.3) to be inhaled with a dry powder inhaler, hence, allowing a local 
treatment at the site of action. 
 
 
Figure 7.8 Remaining CFU in supernatant and biofilm CFU/ml of PAO1 in supernatant and 
biofilm of KRB (control), drug-loaded NPs or Panotile® treated co-cultures was determined 24 h 
after the infection. All planktonic bacteria in supernatant were eradicated when treatment was 
given 1 h after the infection (exception Calu-3, 3 CFU/ml remain after NPs treatment). Later 
application of NPs just increased the CFU/ml slightly. CFU count of biofilm fraction exposed 
that by a later treatment time point the CFU increases. Early treatment (t  = 1 h) nearly 
eradicates all biofilm-grown bacteria. CFU doubles when administration of NPs is conducted at 
t =4 h. Control wells (KRB only) exhibited a log 6 higher CFU/ml than wells that were given 
drug-loaded NPs. Data were log-transformed and are presented as mean ± SEM.  
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7.4 Conclusion 
With the ToxiLight™ bioassay kit the viability of the NPs and their single components 
were determined. In the second highest applied concentration all compounds were well 
tolerated by both epithelial cell lines. Thus, this concentration was used for furth er 
studies. 
In order to find the optimal treatment time point after the infection, a delay of 1 h and 
4 h was chosen to apply the antibiotic-loaded NPs. The Calu-3 cells did not endure the 
circumstances of the infection for long and even with an early treatment (t = 1 h) holes 
in the monolayer, loss of barrier properties and viability was observed. A later 
treatment enhanced these negative effects. No treatment led to a complete 
destruction of the cells and just a bacterial biofilm remained of the co-culture. 
On the other hand, CFBE41o- cells were able to maintain their barrier function and 
viability when treated 1 h after the infection provided they were supplemented with 
human mucus prior to the infection. However, also in the case of this cell line a longer 
delay of the treatment led likewise to monolayer disruption, loss of barrier properties 
and a decreased viability. 
In summary the presented data led to the conclusion that the CFBE41o- cells are the 
superior cell line for the in vitro model. Not just because they feature the most 
common mutation in CF (∆F508-CFTR), which enhances the biofilm formation, but also 
because they proof to be more robust when faced with the bacterial burden, thus, 
offering an appropriate time window to apply and evaluate the novel DDSs. 
The ciprofloxacin-loaded NPs showed a good biocompatibility and no cytotoxic 
potential in the applied concentration (350 µM). They were able to eradicate all 
planktonic bacteria when administered 1 h after the infection and also proved to be 
very effective against free swimming bacteria when treatment was delayed (t  = 4 h). 
Even though a complete elimination of biofilm grown P. aeruginosa was not possible, 
NPs were able to decrease the bacterial load by log 6 and in this context also appear to 
be slightly more effective than the commercially available product Panotile®. These 
data underscore the potential of novel pharmaceutical formulations to deliver 
antibiotics across important biological barriers (e.g., mucus and biofilms) and thus, 
improve the therapy for CF patients in the future. 
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Pulmonary infections with P. aeruginosa unfortunately occur on a daily basis in CF 
patients. Even today these infections are still hard to treat and sooner or later they 
become chronic due to biofilm formation of the pathogen [28]. The resulting pulmonary 
consequences of recurring lung infections and persistent inflammations are still the 
major cause for morbidity and mortality in CF [16]. Novel treatment approaches (e.g., 
with antibiotic loaded nanocarriers) raise hopes to eradicate those persistent 
infections. With the purpose to treat chronic infection right at the site of action, the 
pulmonary application of new drug delivery systems (DDSs) seems a good option. In 
order to evaluate the safety and efficacy of such DDSs, suitable in vitro models are 
necessary before going into pre-clinical trials. 
In this work the development of an in vitro model of human pulmonary epithelial cells 
in co-culture with P. aeruginosa biofilms was conducted. Its applicability for safety and 
efficacy testing of a novel DDSs was evaluated with aerosolized ciprofloxacin-loaded 
NPs. 
Because cell lines offer several advantages over primary cells [106], two human 
bronchial epithelial cell lines were evaluated for this model. During the characterization 
of the two cell lines at hand (i.e., Calu-3 and CFBE41io-), it became evident that the CF 
cell line did not produce mucus, which was in agreement with already published data 
[160, 161]. In addition, the measured barrier properties at ALI conditions were not 
sufficient for an in vitro model. To overcome these obstacles an alternative mucus 
source was utilized. Due to the addition of a human mucus layer on top of the CFBE41o- 
cells, barrier properties increased and moreover, an important part of a CF model, 
mucus, was added. 
P.°aeruginosa was chosen as model pathogen for this CF co-culture model, since it 
becomes the predominant pathogen by late adolescence in CF patients [25, 26]. 
Furthermore, its ability to build biofilms in vitro is well documented in literature [29]. 
Subsequently, different growth media for P. aeruginosa strain PAO1 were assessed in 
order to find the best composition for biofilm formation. A minimal growth medium 
(i.e., M63) supplemented with arginine was selected. 
After the two major components of the in vitro co-culture model were evaluated (i.e., 
human bronchial epithelial cell lines and the CF relevant pathogen P. aeruginosa), in a 
next step planktonic bacteria were used to infect monolayers of the model cell lines 
Calu-3 and CFBE41o-. In both cases, first signs of biofilm development could be 
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measured 4 h after the infection. However, due the rapid overgrowth and resulting 
death of the epithelial cells, this model could not be used to test the novel DDS. 
Therefore, a preformed biofilm, grown for 24 hours externally, was transferred to the 
apical side of the epithelial cell monolayers. The resulting model was incubated for one 
hour before aerosolized ciprofloxacin-loaded NPs where applied. Of note, during the 
whole experimental procedure ALI conditions were maintained. This is an important 
measure when the model is intended for application of pulmonary DDSs (e.g., dry 
powders for inhalation or aerosols). 
During the experimental trials, it turned out that the time point of treatment (i.e., 1 h 
or 4 h after infection) is rather crucial. The co-culture model of Calu-3 and 
P. aeruginosa proofed to be much more vulnerable to the infectious challenge. Even 
with the earlier treatment time point91, barrier function and viability of the cells could 
not be maintained. On the contrary, the CFBE41o- cells proofed to be more robust 
when facing the burden of the infection of a biofilm. The epithelial cells were able to 
maintain their barrier function and viability until 24 h after the infection, but only when 
treatment was applied 1 h after the infection. 
The here used aerosolized NPs showed good biocompatibility and a low cytotoxic 
potential in the chosen concentration. They were able to eradicate all planktonic 
bacteria in the co-culture model after 24 h and could even reduce the number of 
biofilm bound bacteria by log 6. 
Even though a complete eradication of P. aeruginosa biofilm was not possible, further 
tests might shed more light on the efficacy of the novel DDS. Therefore, the application 
of repeated doses might be of interest. Furthermore, also the introduction of additional 
washing steps into the experimental procedure is possible. They could on the one hand 
reduce the bacterial burden of planktonic bacteria on the epithelial cells , and thus 
prolong the viability and applicability of the in vitro model. On the other hand, such 
repeated washing steps could clearly proof the advantage of the DDS compared to free 
drug, since the particles should get entrapped in the mucus biofilm mixture on top of 
the cells and not be rinsed away during the washing steps like the free drug. 
In addition to the mentioned improvements of the model also the use of clinical 
isolates of P. aeruginosa seem of great importance and could enhance the impact of 
the model. 
Summary and Outlook 
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Nevertheless, the experimental set up of a CF relevant in vitro model mimicking the 
biofilm infected lung presented in this work was successfully used to test the efficacy 
and safety of a novel aerosolized DDS. Furthermore, the continuous cultivation of this 
model at ALI conditions makes it valid to be used for potential future trials of dry 
powder formulations together with the PADDOCC system. In such a set-up the here 
applied NPs could be reformulated into microparticels and applied onto the co-culture 
in a formulation that also later would be found in clinical trials. 
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3-D   Three-dimensional 
AET   Antibiotic eradication therapy 
AHL   N-acyl-l-homoserine lactones 
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PPO   Poly propylene oxide 
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